U.S. patent number 6,979,532 [Application Number 10/067,457] was granted by the patent office on 2005-12-27 for process for identifying substances which modulate the activity of hyperpolarization-activated cation channels.
This patent grant is currently assigned to Aventis Pharma Deutschland GmbH. Invention is credited to Andrea Bruggemann, Heinz Gogelein, Holger Heitsch, Hans-Willi Jansen.
United States Patent |
6,979,532 |
Jansen , et al. |
December 27, 2005 |
Process for identifying substances which modulate the activity of
hyperpolarization-activated cation channels
Abstract
The present invention provides a process for identifying
substances that modulate the activity of
hyperpolarization-activated cation channels, and the use of this
process.
Inventors: |
Jansen; Hans-Willi
(Niedernhausen, DE), Bruggemann; Andrea (Frankfurt am
Main, DE), Heitsch; Holger (Mainz-Kastel,
DE), Gogelein; Heinz (Frankfurt am Main,
DE) |
Assignee: |
Aventis Pharma Deutschland GmbH
(Frankfurt am Main, DE)
|
Family
ID: |
7630723 |
Appl.
No.: |
10/067,457 |
Filed: |
February 7, 2002 |
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
|
779587 |
Feb 9, 2001 |
|
|
|
|
Foreign Application Priority Data
|
|
|
|
|
Feb 12, 2000 [DE] |
|
|
100 06 309 |
|
Current U.S.
Class: |
435/4; 435/40;
435/404; 530/350 |
Current CPC
Class: |
G01N
33/6872 (20130101); A61P 9/00 (20180101); G01N
2500/00 (20130101); C12N 2503/00 (20130101) |
Current International
Class: |
C12Q 001/00 ();
C12Q 001/08 (); C12N 005/02 (); C07K 014/00 () |
Field of
Search: |
;435/4,40,404,40.5
;530/350 |
References Cited
[Referenced By]
U.S. Patent Documents
Foreign Patent Documents
|
|
|
|
|
|
|
WO 99/11784 |
|
Mar 1999 |
|
WO |
|
WO 99/32615 |
|
Jul 1999 |
|
WO |
|
WO 99/42574 |
|
Aug 1999 |
|
WO |
|
WO 00/63349 |
|
Oct 2000 |
|
WO |
|
WO 00/73431 |
|
Dec 2000 |
|
WO |
|
Other References
Hodder, et al, 2004, J. Biomol. Screening, 9(5): 417-426. .
Vaccari, T. et al., "The Human Gene Coding for HCN2, a Pacemaker
Channel of the Heart", Biochim. et Biophys. Acta 1446(3):419-425,
1999. .
Biel, M. et al., "Hyperpolarization-Activated Cation Channels: A
Multi-Gene Family", Rev. Physiol. Biochem. Pharmacol. 136:165-181,
1999. .
Hamill, O.P. et al., "Improved Patch-Clamp Techniques for
High-Resolution Current Recording from Cells and Cell-Free Membrane
Patches", Pflugers Arch. 391:85-100, 1981. .
Ludwig, A. et al., "Two Pacemaker Channels from Human Heart with
Profoundly Different Activation Kinetics", EMBO J. 18(9):2323-2329,
1999. .
Langheinrich, U. and Jurgen Daut, "Hyperpolarization of isolated
capillaries from guinea-pig heart induced by K+ channel openers and
glucose deprivation",Journal of Physiolog, 502.2:397-408,
1997..
|
Primary Examiner: Spector; Lorraine
Assistant Examiner: Wegert; Sandra
Parent Case Text
This is a continuation of application Ser. No. 09/779,587, filed
Feb. 9,2001, now abandoned, which is incorporated herein by
reference.
Claims
What is claimed is:
1. A process comprising a) providing, in a suitable container,
cells that express a hyperpolarization-activated cation channel; b)
hyperpolarizing the cells in the presence of a potential-sensitive
fluorescent dye and an isoosmolar sodium-ion-free buffer; c)
optionally, determining the membrane potential of the cells; d)
simultaneously adding sodium ions and a sample containing at least
one substance to be tested for its ability to modulate the activity
of the cation channel; e) determining the membrane potential of the
cells; f) determining whether the membrane potential changed upon
simultaneous addition of sodium ions and the substance(s); and g)
optionally, recording the change in membrane potential, wherein a
change in membrane potential indicates the presence of at least one
substance in the sample that modulates the activity of the cation
channel.
2. The process of claim 1, wherein step c) is performed.
3. The process as claimed in claim 1, wherein the isoosmolar
sodium-ion-free buffer comprises a potassium salt.
4. The process as claimed in claim 1, wherein the isoosmolar
sodium-ion-free buffer comprises potassium ions at a concentration
of at least 0.8 mM.
5. The process as claimed in claim 1, wherein the isoosmolar
sodium-ion-free buffer comprises potassium ions at a concentration
of at least 5 mM.
6. The process as claimed in claim 1, wherein the isoosmolar
sodium-ion-free buffer comprises choline chloride or NMDG
(N-methyl-D-glucamine).
7. The process as claimed in claim 1, wherein the
potential-sensitive dye is an oxonol derivative.
8. The process as claimed in claim 7, wherein the oxonol derivative
is a 3-bis-barbituric acid oxonol.
9. The process as claimed in claim 8, wherein the 3-bis-barbituric
acid oxonol is bis-(1,3-dibutylbarbituric acid)trimethine oxonol
[DiBac.sub.4 (3)], bis-(1,3-diethylthiobarbituric acid)trimethine
oxonol, bis-(1,3-dibutylbarbituric acid)pentamethine oxonol, or a
combination of these.
10. The process as claimed in claim 1, wherein the
potential-sensitive fluorescent dye used is suitable for use in
fluorescent imaging plate reader system.
11. The process as claimed in claim 1, wherein cells having an
elevated intracellular cAMP concentration are used.
12. The process as claimed in claim 11, wherein the intracellular
cAMP concentration is increased by addition of dibutyryl-cAMP or
8-bromo-cAMP.
13. The process as claimed in claim 11, wherein the intracellular
cAMP concentration is increased by addition of an adenylate cyclase
activator.
14. The process as claimed in claim 11, wherein the intracellular
cAMP concentration is increased by addition of forskolin.
15. The process as claimed in claim 14, wherein the intracellular
cAMP concentration is increased by addition of from 1 pM to 100 pM
of forskolin.
16. The process as claimed in claim 11, wherein the intracellular
cAMP concentration is increased by addition of receptor
ligands.
17. The process as claimed in claim 1, wherein the
hyperpolarization-activated cation channel is HCN1, HCN2, HCN3,
HCN4, KAT1, or a heteromultimer of these channels.
18. The process as claimed in claim 1, wherein the
hyperpolarization-activated cation channel is a human
hyperpolarization-activated cation channel.
19. The process as claimed in claim 1, wherein the cells are
mammalian cells.
20. The process as claimed in claim 19, wherein the cells are CHO
or HEK cells.
21. The process as claimed in claim 1, wherein the cells contain a
plasmid which comprises the cDNA of a hyperpolarization-activated
cation channel.
22. The process as claimed in claim 1, wherein the cells comprise a
second plasmid, which comprises the cDNA of the same
hyperpolarization-activated cation channel.
23. The process as claimed in claim 22, wherein the cells comprise
a second plasmid, which comprises the cDNA of a different
hyperpolarization-activated cation channel, such that
heteromultimeric HCN channels can be formed.
24. The process as claimed in claim 1, wherein the cells comprise a
plasmid, which comprises synthetic cDNA encoding at least part of
at least two different cation channels.
25. The process as claimed in claim 1, wherein a change in membrane
potential is measured using a potential-sensitive fluorescent
dye.
26. The process as claimed in claim 25, wherein the
potential-sensitive fluorescent dye is an oxonol derivative.
27. The process as claimed in claim 26, wherein the oxonol
derivative is 3-bis-barbituric acid oxonol.
28. The process as claimed in claim 1, wherein at least one
measurement is carried out in a Fluorescent Imaging Plate Reader
(FLIPR).
29. The process as claimed in claim 1, wherein the change of the
membrane potential of at least two cells is compared.
30. The process as claimed in claim 1, wherein the process is a
high-throughput screening process.
31. The process as claimed in claim 1, wherein the
hyperpolarization-activated cation channel is HCN1, HCN2, HCN3,
HCN4, KAT1, or a heteromultimer of these channels.
Description
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to the field of biological
cell-to-cell communication and electrochemical signalling between
biological cells. In particular, the present invention provides a
process for identifying substances that modulate the activity of
hyperpolarization-activated cation channels, and the use of this
process.
2. Description of the Relevant Art
Some genes of murine and human hyperpolarization-activated cation
channels are already known. Examples include muHCN2(muHAC1) (Ludwig
et al. (1998)), huHCN4 (Ludwig et al. (1999)), huHCN2 (Vaccari, T.
et al. (1999) Biochim. Biophys. Acta 1446(3): 419-425), and those
disclosed in WO 99/32615 and WO 99/42574. See, also, Tables 1-6
herein.
Ludwig et al. (1998) have shown that muHCN2 can be transfected
transiently in HEK293 cells, and that the corresponding channel in
the transfected cells can be examined easily by
electrophysiological methods (patch-clamp studies). The
electrophysiological properties of the cloned channel correspond to
the l.sub.f or l.sub.h current described in pacemaker cells, which
had hitherto not been known on a molecular level (Ludwig et al.
(1998), Biel et al. (1999)). The channel activates when the holding
potential is changed toward hyperpolarization (potential at about
B100 to B160 mV). However, the patch-clamp technique cannot be
automated and is not suitable for high-throughput screening
(HTS).
Using suitable dyes, ion currents can be measured in an FLIPR
(fluorescence imaging plate reader; Molecular Devices, Sunnyvale
Calif., USA). Influx or efflux of ions leads to changes in the
membrane potential, which can be measured in high-throughput
screening in an FLIPR using suitable fluorescent dyes. However, in
contrast to the patch-clamp method, it is not possible to generate
voltage changes in the FLIPR. Voltage changes are, however, an
essential prerequisite for the activation of
hyperpolarization-activated cation channels.
SUMMARY OF THE INVENTION
For the examination of the largest possible number of substances,
we have developed a process that permits, among other things,
high-throughput screening (HTS) for modulators of a
hyperpolarization-activated cation channel.
DETAILED DESCRIPTION OF THE INVENTION
Abbreviations used herein are listed in Table 7 below.
The present invention provides a way to hyperpolarize cells that
express a hyperpolarization-activated cation channel (i.e. to
activate the hyperpolarization-activated cation channel) and to
maintain this hyperpolarization of the cell, for example, until a
measurement of membrane potential can be taken. Under physiological
conditions, a hyperpolarization of the cell that is sufficient to
activate a hyperpolarization-activated cation channel is reversed
by the activity of that channel. Only when hyperpolarization can be
maintained is it possible to measure, for example in an FLIPR, the
depolarization of the cell caused under suitable conditions by a
substance that modulates the activity of the
hyperpolarization-activated cation channel.
Generally speaking, the present invention provides a process for
examining hyperpolarization-activated cation channels. In the
process, cells that express the hyperpolarization-activated cation
channels are hyperpolarized (i.e. the hyperpolarization-activated
cation channel is activated) and this hyperpolarization of the
cells, which is reversed under physiological conditions by the
activity of the hyperpolarization-activated cation channel, is
maintained. By exclusion of extracellular sodium ions, the
activated channel is unable to transport sodium ions into the
cells, i.e. to depolarize the cells. If, simultaneously or even
prior to the addition of the sodium ions, substances are added that
modulate the activity of the hyperpolarization-activated cation
channel, the depolarization is affected. For example, compared to
when only sodium ions are added, depolarization is increased in the
case of HCN activators (for example forskolin) and reduced in the
case of HCN inhibitors (for example zatebradine=3-[3-[[2-(3
,4-dimethoxyphenyl)ethyl]methylamino]propyl]-1,3,4,5-tetrahydro-7,8-dimeth
oxy-2H-3-benzazepin-2-one; Reiffen et al. (1990)).
By measuring the depolarization of the cells or the changes of
their membrane potential, it is possible to identify substances
that modulate the activity of the hyperpolarization-activated
cation channel.
In one aspect, the invention generally provides a process for
identifying substances that modulate the activity of
hyperpolarization-activated cation channels, wherein a) cells which
express a hyperpolarization-activated cation channel are used; b)
the cells are hyperpolarized in the presence of a
potential-sensitive fluorescent dye using an isoosmolar
sodium-ion-free buffer; and c) the change in the membrane potential
of the cells following simultaneous addition of sodium ions and the
substance to be examined is detected and recorded.
Thus, in embodiments, the invention provides a process for
identifying substances that modulate the activity of
hyperpolarization-activated cation channels, wherein the process
comprises a) providing, in a suitable container, cells that express
a hyperpolarization-activated cation channel; b) hyperpolarizing
the cells in the presence of a potential-sensitive fluorescent dye
and an isoosmolar sodium-ion-free buffer; c) optionally,
determining the membrane potential of the cells; d) simultaneously
adding sodium ions and a sample containing at least one substance
to be tested for its ability to modulate the activity of the cation
channel; e) determining the membrane potential of the cells; f)
determining whether the membrane potential changed upon
simultaneous addition of sodium ions and the substance(s); and g)
optionally, recording the change in membrane potential,
wherein a change in membrane potential indicates the presence of at
least one substance in the sample that modulates the activity of
the cation channel.
A suitable container is any container, vessel, receptacle, etc.
that can be used to hold the reagents and samples to be used in the
assay. Suitable containers are disclosed in, or identifiable from,
literature provided by manufacturers of equipment designed to
determine membrane potentials. Such equipment is publicly available
and well known to those of skill in the art.
In embodiments where step "c)" is not performed, a parallel assay,
using the same strain of cells at the same concentration in the
same assay composition, can be run to determine the membrane
potential of the cells in the absence of the sample suspected of
containing at least one substance that can modulate the activity of
a cation channel.
In embodiments, the assay is a high-throughput assay.
In another aspect, the invention generally provides a process for
identifying substances that modulate the activity of
hyperpolarization-activated cation channels, wherein a) cells which
express a hyperpolarization-activated cation channel are used; b)
the cells are hyperpolarized in the presence of a
potential-sensitive fluorescent dye using an isoosmolar
sodium-ion-free buffer; c) the cells are incubated with a substance
to be examined; and d) the change in the membrane potential of the
cells after addition of sodium ions is detected and recorded.
Thus, in embodiments, the invention provides a process for
identifying substances that modulate the activity of
hyperpolarization-activated cation channels, wherein the process
comprises a) providing, in a suitable container, cells that express
a hyperpolarization-activated cation channel; b) hyperpolarizing
the cells in the presence of a potential-sensitive fluorescent dye
and an isoosmolar sodium-ion-free buffer; c) optionally,
determining the membrane potential of the cells; d) incubating the
cells with a sample containing at least one substance to be tested
for its ability to modulate the activity of the cation channel; e)
optionally, determining the membrane potential of the cells; f)
optionally, determining whether the membrane potential changed upon
addition of the substance(s) to be tested; g) adding sodium ions;
h) determining the membrane potential of the cells; i) determining
whether the membrane potential changed upon addition of the sodium
ions; and j) optionally, recording the change in membrane
potential, wherein a change in membrane potential between the time
before the sodium ions are added and after the sodium ions are
added indicates the presence of at least one substance in the
sample that modulates the activity of the cation channel.
Extracellular potassium ions can be included in the assay. In
certain situations, these ions can improve the function of the
hyperpolarization-activation cation channels. For example, they
might be included when HCN (HAC) channels are being used in the
process. Thus, in embodiments of the present invention, the
isoosmolar sodium-ion-free buffer comprises potassium ions
(K.sup.+). In embodiments, the buffer comprises potassium ions in
the form of potassium chloride. In embodiments, the buffer
comprises potassium ions at a concentration of at least about 0.5
mM K.sup.+. In embodiments, the buffer comprises potassium ions at
a concentration of at least about 0.8 mM K.sup.+. In embodiments,
the buffer comprises potassium ions at a concentration of about 2
mM. In embodiments, the buffer comprises potassium ions at a
concentration of about 5 mM.
In embodiments, the isoosmolar sodium-ion-free buffer comprises at
least one cation that is not able to cross the membrane in amounts
that correspond to the normal extracellular sodium ion
concentration. For example, the buffer can comprise choline, for
example in the form of choline chloride, or NMDG
(N-methyl-D-glucamine). In embodiments, the isoosmolar
sodium-ion-free buffer comprises both potassium ions and at least
one cation that is not able to cross the membrane in amounts that
correspond to the normal extracellular sodium ion
concentration.
In embodiments, the isoosmolar sodium-ion-free buffer comprises a
potential-sensitive dye, for example a potential-sensitive
fluorescent dye. Included among these are oxonol derivatives, such
as 3-bis-barbituric acid oxonol. Thus, in embodiments, the
isoosmolar sodium-ion-free buffer comprises potassium ions, at
least one cation that is not able to cross the membrane in amounts
that correspond to the normal extracellular sodium ion
concentration, and a potential-sensitive dye.
In embodiments, the buffer comprises potential-sensitive
fluorescent dyes that are suitable for examining the membrane
potential of nonexcitable cells. Examples of such dyes include, but
are not limited to, potential-sensitive slow-response dyes.
Non-limiting examples of such potential-sensitive slow-response
dyes include bis-(1,3-dibutylbarbituric acid)trimethine oxonol
[DiBac.sub.4 (3)], bis-(1,3-diethylthiobarbituric acid)trimethine
oxonol [DiSBac.sub.2 (3)] or bis-(1,3-dibutylbarbituric
acid)pentamethine oxonol [DiBac.sub.4 (5)]. Other known and
suitable potential-sensitive dyes include, but are not limited to,
fast-response dyes (for example, of the styrylpyridinium type),
which are used in certain embodiments in conjunction with excitable
cells, such as neurons, cardiac cells, etc. These
potential-sensitive dyes react in the millisecond range and are not
particularly sensitive (2-10% fluorescence change per 100 mV
potential change). Other suitable dyes include slow-response dyes
of the carbocyanine type. Non-limiting examples of these
slow-response dyes include diOC5(3)-3,3'-dipentyloxacarbocyanine
iodide, diOC6(3)-3,3'-dihexyloxacarbocyanine iodide, etc.), JC-1
(5,5',6,6'-tetrachloro-1,1'-3,3'-tetraethylbenzimidazolecarbocyanine
iodide), and rhodamine 123. In embodiments, these slow-response
potential-sensitive dyes are used in studies of the membrane
potential of mitochondria.
One embodiment of the invention relates to the use of the
fluorescent dye from the FLIPR Membrane Potential Assay Kit
(Molecular Devices, Sunnyvale, Calif., USA). The fluorescence of
this dye can be measured using a standard emission filter, which is
transparent between about 510 and about 580 nm. In embodiments,
fluorescence of this dye is measured using a filter that is
transparent above about 550 nm. The manufacturer of this dye and
kit disclose a number of advantages of their product, over, for
example, assays based on DiBac.sub.4 (3), and these advantages can
be applicable to the present invention.
Some of these advantages include: 1) the measurement of membrane
potentials with the kit is not temperature sensitive, in contrast
to DiBac.sub.4 (3), where the temperature has to be equilibrated
prior to the actual measurement in the FLIPR; 2) the volume added
in the FLIPR can be greater than that in the case of DiBac.sub.4
(3), where usually all substances have to be added in a 10-fold
concentrated form; 3) the measurements can be carried out much more
rapidly, since the kit requires a much shorter time to reach the
steady state than DiBac.sub.4 (3), which usually requires between
10 and 30 minutes; 4) for many measurement protocols, a washing
step prior to the addition of the dye is no longer required; and 5)
the dye does not have to be present in each solution.
In embodiments of the present invention, the first two advantages
are relied upon because these two advantages can be applied to
assays of hyperpolarization-activated cation channels. The first
two advantages can also be applied to embodiments of the invention
that are directed to high-throughput screening, since screening of
a large number of samples at once can be complicated and/or time
consuming. For example, in embodiments where FLIPR II, which allows
the measurement in 384-well plates and which is preferably employed
for high-throughput screening thermostating, is used, these first
two advantages can reduce the complications and time necessary to
perform the assay process. In the case of poorly soluble
substances, it is furthermore an advantage if they can be added to
the cells in five-, three-, or even two-fold concentrated form
instead of 10-fold concentrated form, as is typical with
DiBac.sub.4 (3).
In the processes of the present invention, cells having an elevated
intracellular cAMP concentration can be used. Elevated
intracellular cAMP concentrations can be achieved, for example, by
adding cAMP derivatives that are able to cross the membrane.
Non-limiting examples of such derivatives include dibutyryl-cAMP
and 8-bromo-cAMP. As a further non-limiting example, the
intracellular cAMP concentration can be increased by the addition
of an adenylate cyclase activator, for example forskolin. When
forskolin is used, successful results can be obtained when it is
supplied in concentrations of less than about 100 .mu.M. For
example, forskolin can be used at a concentration of between about
1 .mu.M and about 100 .mu.M. It can also be used at concentrations
less than about 1 .mu.M. In embodiments, it is used at a
concentration of about 10 .mu.M. In principle, it is also possible
to use all substances or ligands that activate adenylate cyclase by
signal transduction in the cell line employed (for example ligands
for b-adrenergic receptors, such as adrenalin, isoproterenol,
noradrenalin, etc., if the cell has endogenous b-adrenergic
receptors).
To depolarize the membrane potential, Na.sup.+ (which can be
supplied in the form of NaCl, for example) is added in the FLIPR to
the cells which have hyperpolarized by the sodium-ion-free buffer.
In embodiments, the Na.sup.+ is added to achieve a final Na.sup.+
concentration of about 20-100 mM. In embodiments, it is added to
achieve a final Na.sup.+ concentration of about 50 mM. In
embodiments where the FLIPR Membrane Potential Assay Kit (Molecular
Devices, Sunnyvale, Calif., USA) is used, the final Na.sup.+
concentration can be about 20-100 mM. For example, it can be about
40-80 mM.
In embodiments, the invention relates to processes in which the
hyperpolarization-activatable cation channel is an HCN1, HCN2,
HCN3, HCN4 channel (where HAC1=HCN2, HAC2=HCN1, HAC3=HCN3 and
HAC4=HCN4) or a KAT1 (=AKT) channel (hyperpolarization-activated
potassium channel from Arabidopsis thaliana); a heteromultimer of
these channels (i.e. a channel which is composed of subunits of
different hyperpolarization-activated cation channels); or a
chimeric hyperpolarization-activated cation channel (i.e. a
synthetic channel in which individual subunits are composed of
parts of different channels or hyperpolarization-activated cation
channels). The hyperpolarization-activated cation channel is
preferably a human hyperpolarization-activated cation channel, for
example huHCN2, (SEQ ID NO. 1, SEQ ID NO. 2) or huHCN4 (SEQ ID NO.
3, SEQ ID NO. 4), or a murine hyperpolarization-activated cation
channel muHCN2 (SEQ ID NO. 5, SEQ ID NO. 6). See Tables 1-6. On the
amino acid level, the identity between muHCN2 and huHCN2 is 94.8%.
In principle, the process is suitable for all cation channels which
are activated by hyperpolarization. For example, it is suitable for
HCN1-4 (or HAC1-4; see Biel et al. (1999)).
The cells can be any eukaryotic cells. For example, the cells can
be mammalian cells, such as CHO or HEK293 cells. In embodiments,
CHO cells or another cell line having comparably few endogenous
potassium channels are used, since endogenous potassium channels
might interfere with the measurement, for example, in the FLIPR. In
other embodiments cells whose endogenous potassium channels are not
functionally expressed (for example the corresponding knock-out
cells) are used.
The cells can, but do not necessarily, contain nucleic acids (i.e.,
RNA, DNA, PNA) that code for the hyperpolarization-activated cation
channel. In embodiments, the cells contain DNA. In embodiments, the
cells contain RNA. In embodiments, the cells contain a eDNA of a
hyperpolarization-activated cation channel in a suitable plasmid.
Such cells can be prepared by transfecting the original cell line
with a plasmid that contains the cDNA of a
hyperpolarization-activated cation channel. Other techniques can be
used as well. Techniques for introducing heterologous nucleic acids
into cells are well known and widely practiced by those of skill in
the art, and thus need not be detailed here.
In the case of the hyperpolarization-activated cation channels, it
is an object of the invention to detect, and optionally, record
changes in the membrane potential of the cells, where the changes
are the result of the activation or the inhibition of these
channels. Detection can utilize bis-barbituric acid oxonols. Three
bis-barbituric acid oxonols (see, for example, "Handbook of
Fluorescent Probes and Research Chemicals", 6th edition, Molecular
Probes, Eugene Oreg., USA), which are mainly referred to as DiBac
dyes, form a family of potential-sensitive dyes having excitation
maxima at 490 nm (DiBac.sub.4 (3)), 530 nm (DiSBac.sub.2 (3)), and
590 nm (DiBac.sub.4 (5)). The dyes get into depolarized cells by
binding to intracellular proteins or membranes, leading to
increased fluorescence and a red shift. Hyperpolarization results
in the expulsion of the anionic dyes and thus in a decrease in
fluorescence. This decrease in fluorescence can be measured, for
example, with the measuring device FLIPR. Accordingly, one
embodiment of the invention relates to the measurement of the
membrane potential in a Fluorescent Imaging Plate Reader
(FLIPR).
The FLIPR (for: Fluorescent Imaging Plate Reader; Manufacturer:
Molecular Devices, Sunnyvale, Calif., USA) is a measuring device
that allows the simultaneous measurement of changes of the
fluorescence intensity in all wells of a microtiter plate. The dyes
used are excited at about 488 nm using an argon laser, which is
integrated into the system. The standard emission filter of the
system is transparent in the range from 510 B 580 nm. The emitted
fluorescence is registered using a CCD camera, and the system
permits the simultaneous recording, within an interval of about one
second, of the fluorescence in all wells of a 96-well or 384-well
microtiter plate. Using a built-in pipettor, it is even possible to
determine the fluorescence during the addition of the substance,
which can be beneficial, for example, in the case of rapid
processes. By means of special optics, the fluorescence can be
registered in a layer of only about 50 mm, but not in the entire
well. This can be beneficial for background reduction in all
measurements where the fluorescent dye is also present
extracellularly. Such a situation can exist, for example, in the
measurement of changes in membrane potential using DiBac dyes.
Standard applications of the system are measurements of the
intracellular calcium concentration or the membrane potential of
cells. Among the dyes mentioned above, DiBac.sub.4 (3), which,
owing to its excitation maximum, is most suitable for the argon
laser in the FLIPR, has the highest sensitivity for voltage
differences.
Since the DiBac.sub.4 (3) takes some time to come to equilibrium,
the measurement can be taken after a certain incubation time. In
embodiments, the incubation temperature is at or about the optimal
temperature for growth and metabolism of the biological cells being
used in the assay. For example, the incubation temperature can be
at or about 37.degree. C. Incubation time can be varied to achieve
complete or uniform sample temperature. In embodiments, the sample
can be incubated for at least about 10 minutes. In embodiments, the
sample is incubated for about or precisely 30 minutes.
Although results can be obtained at any time desired, in order to
obtain as reliable of a result as possible or practical, the
results should be determined and, optionally, recorded as quickly
as possible after each incubation step. This is because cooling of
the dye solution might affect the result of the measurement. Thus,
prior to any measurement, the composition to be measured can be
incubated at a chosen temperature for a period of time that is
sufficient to equilibrate the temperature of the composition at a
desired level. For example, the composition can be incubated for at
least about one minute, or at least about two, three, for, five, or
even more minutes. Included are incubation periods prior to initial
measurements (e.g., to determine base-line levels of activity or
membrane potential). As with the other incubation periods, this
pre-incubation phase can be carried out to compensate for
temperature variations on the microtiter plate.
In embodiments where FLIPR is used, the measurement is typically
carried out using the temperature parameters preset by the FLIPR
manufacturer for the measurement of membrane potentials (about
37.degree. C.). However, this is a guideline, and those practicing
the invention can alter the temperature to achieve maximal results.
Such temperature modifications are well within the skill of those
in the art, and do not represent undue experimentation. In
embodiments, the parameters preset by the FLIPR manufacturer are
followed essentially precisely.
Although variations in volume can be accounted for, in the FLIPR,
in embodiments of the present invention, the volume of the reaction
solution in which the process is carried out is changed as little
as possible. In embodiments where DiBac.sub.4 (3) is used, the
DiBac.sub.4 (3) signal is most reproducible if only relatively
small volume changes take place in the FLIPR; thus, the volume is
typically maintained throughout, to the extent possible and
practicable. Accordingly, in these embodiments, the substances to
be tested are added as concentrated solutions. In embodiments, they
are added at a concentration of at least about 2-fold. For example,
they can be added in about a five-fold, ten-fold, or even greater
concentrated form to the DiBac.sub.4 (3)-dyed cells.
Since the fluorescence measurement with the FLIPR Membrane
Potential Assay Kit is not temperature-sensitive, it can be carried
out simply at room temperature. This can be advantageous, for
example, in embodiments that utilize the FLIPR II, which allows
measurements with 384-well microtiter plates.
In embodiments, the HCN channels are activated by hyperpolarization
(for example HCN2 at B100 mV to about 50%) and cause a
depolarization of the cells. By increasing the intracellular cAMP
concentration (for example with dibutyryl-cAMP or with forskolin),
the value of the half-maximal activation can be shifted by about 10
mV to more positive potentials (Ludwig et al., 1998).
Electrophysiologically, HON channels can be studied easily on
stably transfected cells using the patch-clamp method, as voltage
changes can be brought about easily. In contrast, in the FLIPR, it
is not possible to induce voltage changes, and exactly because of
the HCN activity, a hyperpolarization of the cells would only be
transient. It has not been possible to achieve hyperpolarization of
the transfected cells by adding an HCN2 inhibitor (zatebradine),
since the resting membrane potential of the transfected cells is
much too far removed from the potentials at which HCN2 is
activated.
On the one hand, hyperpolarization is required for HCN activation.
However, on the other hand, under physiological conditions, an
activated HCN leads immediately to depolarization. Accordingly, in
the present invention, conditions are provided under which the HCN
channels can be activated by hyperpolarization, but where
depolarization by the activated HCN channel is initially
impossible. To this end, the cells, for example cells seeded in
microtiter plates, are washed in an isoosmolar buffer in which NaCl
has been replaced by another chloride salt, such as choline
chloride. In embodiments, the wash buffer also contains at least
some KCl, since extracellular K.sup.+ can improve HCN activation
(Biel et al. 1999). In embodiments, the wash buffer contains at
least 1 mM KCl. In embodiments, the wash buffer contains about 5 mM
KCl. The wash buffer, which serves to effect hyperpolarization of
the cation channels and thus the HCN cells, can also contain 5
.mu.M DiBac.sub.4 (3) for measuring changes in the membrane
potential in the FLIPR. By removing the extracellular Na.sup.+, the
cells are hyperpolarized, i.e. the cation channel is activated.
However, the HCN is not capable of causing depolarization of the
cells, since the required concentration gradient of the ions
Na.sup.+ or K.sup.+ transported by HCN is missing. Here, an
activated HCN could only result in a more pronounced
hyperpolarization. This is reflected in the fact that the initial
fluorescence measured for HCN cells in the FLIPR at 10 .mu.M
forskolin is lower than that without forskolin, whereas there is no
difference in nontransfected cells.
In the FLIPR, Na.sup.+ is added to the cells, so that the activated
HCN (after a few seconds, in which there are mixing effects)
causes, from about 15 seconds after the addition of Na.sup.+,
depolarization of the cells, which becomes visible by an increase
in fluorescence. The detection of HCN modulators can rely on a
difference between cells having an activated HCN channel (e.g.,
only Na.sup.+ addition) and cells having a blocked HCN channel
(e.g., Na.sup.+ +8 mM CsCl). It has been determined that a greater
difference provides a greater reliability in the system. For
example, activation of the HCN channel by pre-incubation with 10
.mu.M forskolin increases the difference between the uninhibited
100% value from the inhibited 0% value considerably.
One embodiment of the present invention relates to the comparative
determination of the change in the membrane potential of at least
two cell populations incubated with different concentrations of one
of the substances to be examined. In this way, the optimal
concentration of the substance(s) can be determined.
Substances that are to be examined for their activity are referred
to as substances to be examined or substances to be tested.
Substances that are active, i.e. that modulate the activity of the
hyperpolarization-activated cation channel, can either be
inhibitors (they inhibit the channel and reduce depolarization or
prevent depolarization altogether) or be activators (they activate
the channel and cause a more pronounced or more rapid
depolarization) of the hyperpolarization-activated cation
channel.
In embodiments, the invention provides a high-throughput screening
(HTS) process. In HTS, the process can be used for identifying
inhibitors and/or activators of a hyperpolarization-activated
cation channel. Substances identified in this manner can be used,
for example, as pharmaceutically active compounds. Thus, they can
be used as medicaments (medicinal compositions) or as active
ingredients of medicaments.
Accordingly, the invention also provides a process that comprises
the formulation of an identified substance in a pharmaceutically
acceptable form. In this aspect of the invention, the methods
described above can be linked to formulation of an identified
substance in a pharmaceutically acceptable form. Such forms, and
processes for preparing such forms, are well known to, and widely
practiced by, those of skill in the art. Therefore, they need not
be detailed here. Examples include, but are not limited to, forms
that comprise excipients or biologically tolerable carriers.
The invention also provides a process for preparing a medicament.
The process comprises the identification of a substance that
inhibits or activates the activity of a hyperpolarization-activated
cation channel, and mixing the identified substance with a
pharmaceutically acceptable excipient. In embodiments, the process
for preparing a medicament comprises a) the identification of a
substance which modulates the activity of
hyperpolarization-activated cation channels; b) the preparation of
the substance; c) the purification of the substance; and d) the
mixing of the substance with a pharmaceutically acceptable
excipient.
The invention also provides a kit. In embodiments, the kit is a
test kit for determining whether a substance modulates the activity
of a hyperpolarization-activated cation channel. In embodiments,
the test kit comprises a) cells that overexpress a
hyperpolarization-activated cation channel; b) an isoosmolar
sodium-ion-free buffer for hyperpolarizing the cell; and c) at
least one reagent for detection of hyperpolarization activated
cation channels.
The components/reagents can be those described in detail herein
with respect to the assays of the invention. The components can be
supplied in separate containers within the kit or in combinations
within containers within the kit. Where applicable, components
and/or reagents can be supplied in stabilized form. The stabilized
form can permit the components and/or reagents to be maintained for
extended periods of time without significant degradation or loss in
activity. For example, the cells can be supplied in a cryogenic
state. In addition, the salts (ions) or reagents that will comprise
the assay composition can be provided in solid (dry) form, to be
reconstituted with water or another appropriate solvent prior to
use. Accordingly, the kit can comprise water.
As a measure for the activity of a substance, the change in the
membrane potential of the cell is measured, for example, with the
aid of a potential-sensitive fluorescent dye. As mentioned above,
the dye can be an oxanol derivative, such as 3-bis-barbituric acid
oxanol.
EXAMPLES
The invention will now be illustrated in more detail by various
examples of embodiments of the invention. The following examples
are exemplary only. Thus, the scope of the invention is not limited
to the embodiments disclosed in the examples. Abbreviations used in
the Examples are listed in Table 7 below.
Example 1
Preparation of Transfected Cells
The plasmid pcDNA3-muHCN2 contains the murine HCN2 (muHCN2) cDNA
(Genbank Accession No. AJ225122) of Pos. 22-2812 (coding sequence:
Pos. 36-2627), cloned into the EcoRI and NotI cleavage sites of
pcDNA3, and was obtained from M. Biel, TU Munich (Ludwig et al.,
1998). In each case 6 .mu.g of this plasmid DNA were used for
transfecting CHO or HEK293 cells. For transfecting CHO cells or HEK
cells, the LipofectAmine.TM. Reagent from Life Technologies
(Gaithersburg, Md., USA) was used, in accordance with the
instructions of the manufacturer. 24 hours after the transfection,
the cells were transferred from culture dishes into 75 cm.sup.2
cell culture bottles. 72 hours after the transfection, the cells
were subjected to a selection with 400 .mu.g/ml of the antibiotic
G418 (Calbiochem, Bad Soden, Germany). Following a two-week
selection, the surviving cells were detached from the bottles using
trypsin-EDTA, counted in the cell counter Coulter Counter Z1 and
sown into 96-well microtiter plates such that statistically, 1 cell
was present per well. The microtiter plates were checked regularly
under the microscope, and only cells from wells in which only one
colony was growing were cultured further.
From these cells, total RNA was isolated with the aid of the
QlAshredder and RNeasy kits from Qiagen (Hilden, Germany). This
total RNA was examined by RT-PCR for expression of muHCN2 (Primer
1): 5'-GCCAATACCAGGAGAAG-3' [SEQ ID NO. 7], corresponds to Pos.
1354-1370 and AJ225122, and primer 2:5'-TGAGTAGAGGCGACAGTAG-3' [SEQ
ID NO. 8], corresponds to pos. 1829-1811 in AJ225122; expected
RT-PCR band: 476 bp.
Example 2
Patch-Clamp Examination of the Cells
Using the patch-clamp method, the cells with detectable mRNA
expression were examined electrophysiologically, in the whole-cell
configuration, for functional expression of muHCN2. This method is
described in detail in Hamill et al (1981), which is incorporated
herein by reference. The cells were clamped to a holding potential
of -40 mV. Starting with this holding potential, the ion channels
were activated by a voltage change to B140 mV for a period of one
second. The current amplitude was determined the end of this pulse.
Among the transfected HEK cells, some were found having currents of
about 1 nA; however, owing to interfering endogenous currents, it
was not possible to construct an assay for these cells in the
FLIPR.
However, in the HEK cells, it was found clearly that a functionally
active HCN2 channel was only detectable in cells having strong mRNA
expression. In the CHO cells, the correlation between mRNA
expression and function was confirmed. In general, the mRNA
expression in the HEK cells was about three times better than that
in the CHO cells. In the patch-clamp studies, it was possible to
demonstrate a weak current in some cells of one of the most
strongly expressing CHO cell lines.
Example 3
Preparation of Doubly-Transfected Cells
Since the functional expression appeared to correlate strongly with
the mRNA expression, we carried out a second transfection with the
muHCN2 cDNA that had earlier been cloned into the EcoRI and NotI
site of the vector pcDNA3.1(+)zeo. After a two-week selection with
G418 and Zeocin (Invitrogen, Groningen, NL), individual cell clones
were isolated as described in Example 1. Following isolation of the
total RNA from these cells, an RT-PCR with the primers mentioned in
Example 1 was carried out. Then an RT-PCR was carried out with the
following primers, comprising a region which contains the 3'-end of
the coding sequence of muHAC1 (primer 3:
5'-AGTGGCCTCGACCCACTGGACTCT-3' [SEQ ID NO. 9], corresponds to pos.
2553-2576 in AJ225122, and primer 4:
5'-CCGCCTCCTAAGCTACCTACGTCCC-3' [SEQ ID NO. 10], corresponds to
pos. 2725-2701 in AJ225122).
Some of the doubly-transfected cells showed a considerably more
pronounced expression both in RT-PCR and in the patch-clamp
analysis than the cells which had been transfected only once.
Electrophysiologically, currents of up to 11 nA were measured.
These cells were used for constructing an FLIPR assay for HCN2.
Example 4
Construction of an FLIPR Assay for HCN Channels
The cells seeded on the microtiter plates are washed in an
isoosmolar buffer in which NaCl has been replaced by choline
chloride. However, this wash buffer also contains 5 mM KCl, since
extracellular K.sup.+ is important for HCN activation (Biel et al.
1999). This wash buffer, which serves to effect hyperpolarization
of the HCN cells, also contains 5 .mu.M DiBac.sub.4 (3) for
measuring changes in the membrane potential in the FLIPR. By
removing the extracellular Na.sup.+, the cells are hyperpolarized,
i.e. the HCN is activated. However, the HCN is not capable of
causing depolarization of the cells, since the required
concentration gradient of the ions Na.sup.+ or K.sup.+ transported
by HCN is missing. Here, an activated HCN could only result in a
more pronounced hyperpolarization. This is reflected in the fact
that the initial fluorescence measured for HCN cells in the FLIPR
at 10 .mu.M forskolin is lower than that without forskolin, whereas
there is no difference in nontransfected cells.
Since DiBac.sub.4 (3) fluorescence may be sensitive to temperature
variations, the measurement is, after an incubation at 37.degree.
C. for 30 minutes, carried out as quickly as possible--cooling of
the dye solution may affect the measured results. Preferably, the
sample is thermostated for five minutes in the FLIPR prior to the
start of the measurement.
The substances to be tested are preferably added in 10-fold
concentrated form to the cells which had been dyed with DiBac.sub.4
(3).
In the FLLPR, Na.sup.+ is added to the cells so that the activated
HCN (after a few seconds, in which there are mixing effects)
causes, from about 15 seconds after the addition of Na.sup.+,
depolarization of the cells, which becomes visible by an increase
in fluorescence. An activation of the HCN channel by preincubation
with 10 .mu.M forskolin increases the difference between the
uninhibited 100% value from the inhibited 0% value considerably. By
comparison with the control values, it can be detected whether a
substance to be tested is an activator (more rapid or more
pronounced depolarization) or an inhibitor (slower or inhibited
depolarization).
Example 5
Determination of the IC50 of an HCN2 Blocker
Using the transfected HCN cells, the effect of various
concentrations of the substance zatebradine, which is known as an
I.sub.f blocker, were examined. The inhibition by zatebradine was
calculated from the relative change in fluorescence from the time
60 seconds. For each concentration of the inhibitor, the mean of in
each case 6 wells of the microtiter plate was determined. From
these values, the IC50 of zatebradine was calculated as 26 .mu.M, a
value which corresponds well with the value of 31 .mu.M determined
electrophysiologically in the same cells.
Example 6
Use of the FLIPR Membrane Assay Kit (Molecular Devices, Sunnyvale,
USA):
Cells that were seeded a day earlier are, as before, washed three
times with in each case 400 .mu.l of wash buffer per well. However,
this time, the volume that remains above the cells after the last
washing step is chosen depending on the desired Na.sup.+ and
Cs.sup.+ concentrations. The dye, in wash buffer, is added, and the
cells are incubated with dye for 30 minutes. The temperature is
typically room temperature (about 21-25.degree. C.), but can be
about 37.degree. C.
In the FLIPR, depolarization is then induced by addition of
Na.sup.+ and in some control wells inhibited again by simultaneous
addition of Cs.sup.+. Since, in the dye from Molecular Devices, an
increase in the ionic strength might lead to changes in
fluorescence, it has to be ensured that the ionic strength changes
to the same degree in all wells of a microtiter plate. The desired
final concentrations of sodium or cesium ions permitting, the
osmolarity is not changed. To adjust the desired concentrations of
Na.sup.+ and Cs.sup.+, two further buffers which, instead of 140 mM
of choline chloride, contain 140 mM NaCl (sodium buffer) and 140 mM
CsCl (cesium buffer), respectively, are used in addition to the
wash buffer.
For measurements with the FLIPR Membrane Potential Assay Kit
Molecular Devices gives the following standard protocol for 96-well
microtiter plates (384 wells in brackets): On the day before the
measurement, the cells are seeded in 100 ml (25 ml) of medium.
Following addition of 100 .mu.l (25 .mu.l) of dye and 30 minutes of
incubation at room temperature or at 37.degree. C., 50 .mu.l (25
.mu.l) of the substance to be tested, in a suitable buffer, are
added in the FLIPR.
Using the volumes stated by Molecular Devices, it is possible,
without changing the ionic strength, to achieve a maximum
concentration of 28 mM for Na.sup.+ +Cs.sup.+ in 96-well plates and
a maximum concentration of 46.7 mM in 384-well plates. Since this
concentration, in particular in the 96-well plates, is too low for
optimum activity of the hyperpolarization-activated cation
channels, different volumes are tested for the individual
steps.
It has been found that the dye concentrations can be reduced to
half of those in the protocol given by Molecular Devices.
In 96-well plates, good results are obtained even with the
following volumes: 45 .mu.l of wash buffer supernatant above the
cells, 60 .mu.l of dye in the wash buffer, 195 .mu.l addition
volume in the FLIPR. Such a high additional volume allows a maximum
concentration of Na.sup.+ +Cs.sup.+ of 91 mM, i.e. at 8-10 mM CsCl,
the final NaCl concentration can be 81-83 mM. For 80 mM Na.sup.+
and 8 mM Cs.sup.+, 6.43 .mu.l of wash buffer, 171.43 .mu.l of
sodium buffer and 17.14 .mu.l of cesium buffer are required, based
on an added volume of 195 .mu.l.
Materials and Methods
The following materials and methods were, and can be, used to
practice the invention as described in the Examples above. Other
materials and methods can be used to practice other embodiments of
the invention. Thus, the invention is not limited to the materials
and methods disclosed below.
1. Solutions and buffers for the measurement with DiBac.sub.4 (3)
A: DiBac.sub.4 (3) bis-(1,3-dibutylbarbituric acid)trimethine
oxonol From Molecular Probes, Cat. No. B-438, MW: 516.64 g/mol
A 10 mM stock solution of DiBac.sub.4 (3) is made up in DMSO (25 mg
of DiBac.sub.4 (3)/4.838 ml of DMSO). Aliquots of this stock
solution are stored at -20.degree. C. Final concentration during
dyeing and addition: 5 .mu.M. B: Forskolin MW: 410.5 g/mol Final
concentration during dyeing: 10 .mu.M Aliquots of a 10 mM stock
solution in DMSO are stored at -20.degree. C. C: Wash buffer: (140
mM choline chloride, 5 mM KCl, 1 mM CaCl.sub.2, 1 mM MgCl.sub.2, 10
mM HEPES, 5 mM glucose, adjusted to pH 7.4 with 1 M KOH) D: Presoak
solution for saturating the tips of the pipettes: as wash buffer+10
.mu.M DiBac.sub.4 (3) This solution is only used for the presoak
plate. E: Dye solution: double concentrated, i.e. wash buffer+10
.mu.M DiBac.sub.4 (3)+20 .mu.M forskolin F: 10-fold concentrated
solution for the addition plate: 500 mM NaCl in H.sub.2 O+5 .mu.M
DiBac.sub.4 (3) All substances are made up in this solution in
10-fold concentrated form. Positive control (final concentration):
50 mM NaCl Negative control (final concentration): 50 mM NaCl+8 mM
CsCl
2. Solutions and buffers for the measurements with the FLIPR
Membrane Potential Assay Kit from Molecular Devices A: FLIPR
Membrane Potential Assay Kit, from Molecular Probes, Cat. No. R8034
B: Wash buffer: (140 mM choline chloride, 5 mM KCl, 1 mM
CaCl.sub.2, 1 mM MgCl.sub.2, 10 mM HEPES, 5 mM glucose, adjusted to
pH 7.4 with 1M KOH). C: Dye buffer: (content of one of the "reagent
vials" of the FLIPR Membrane Potential Assay Kit in 10 ml of wash
buffer) D: Sodium buffer: (140 mM NaCl, 5 mM KCl, 1 mM CaCl.sub.2,
1 mM MgCl.sub.2, 10 mM HEPES, 5 mM glucose, adjusted to pH 7.4 with
1M KOH). E: Cesium buffer: (140 mM CsCl, 5 mM KCl, 1 mM CaCl.sub.2,
1 mM MgCl.sub.2, 10 mM HEPES, 5 mM glucose, adjusted to pH 7.4 with
1M KOH).
3. Cell culture operations:
The day before the measurement, the muHCN2-transfected CHO cells
are seeded at a density of 35 000 cells/well, in each case in 200
.mu.l of complete medium, into black 96-well microtiter plates. The
cells are incubated at 37.degree. C. and 5% CO.sub.2 overnight.
4. Dyeing with DiBac.sub.4 (3) and measurement in FLIPR:
Before dyeing, the cells are washed three times with 400 .mu.l of
wash buffer in a cell washer. After the last washing step, a
residual volume of 90 .mu.l of wash buffer/well remains above the
cells.
The washed cells (with 90 .mu.l of wash buffer/well) are in each
case incubated with 90 .mu.l of dye solution/well at 37.degree. C.
in the CO.sub.2 incubator for 30 minutes. After this incubation
time, the cell plate is measured in the FLIPR at about 37.degree.
C. (preset temperature setting of the FLIPR manufacturer for
measurement of membrane potentials with DiBac.sub.4 (3)), either
immediately or after five minutes of thermostating.
The snapshot (initial fluorescence before the start of the
measurement) should on average be about 35 000 units. In the
maximum, the FLIPR can resolve up to about 65 000 units.
When the program is started, the tips of the pipettes are initially
saturated by immersion into presoak solution with DiBac.sub.4 (3).
Following this step, the actual measurement is initiated with the
first measurement (t=0 seconds). Since DiBac.sub.4 (3) is a
slow-response dye, it is sufficient to determine the fluorescence
in the wells of the microtiter plate every 5 seconds. After about
20 seconds, the substances, which are present in the addition plate
in 10-fold concentrated form, are added simultaneously to the
microtiter plate using the pipettor. Since the volume after dyeing
is 180 .mu.l, 20 .mu.l are added to each well. The measurement of
the fluorescence can be terminated after about 5 minutes. For
evaluation, the change in fluorescence in the interval where it is
linear and in which uninhibited HCN2-transfected cells differ
significantly from inhibited cells is examined.
5. Dyeing with the FLIPR Membrane Potential Assay Kit and
measurement in the FLIPR.
Before dyeing, the cells are washed three times with 400 .mu.l of
wash buffer in a cell washer. After the last washing step, a
residual volume of 45-90 .mu.l of wash buffer/well remains above
the cells.
Following addition of the dye solution (the volume depends on the
desired final concentrations), the samples are incubated at room
temperature (preferred) or at 37.degree. C. in a CO.sub.2 incubator
for 30 minutes. Following this incubation time, the cell plate is
measured at room temperature in the FLIPR.
In the FLIPR Membrane Potential Assay Kit the snapshot (initial
fluorescence before the start of the measurement) may be lower than
that during the measurement with DiBac.sub.4 (3), since the assay
kit is more sensitive to changes in the membrane potential than
DiBac.sub.4 (3).
Owing to the higher achievable sensitivity, the measurement should,
wherever possible (FLIPRII), be carried out using an emission
filter which is transparent to light above 550 nm. However, it is
also possible to carry out the measurements using the standard
filter, which is transparent between 510 and 580 nm.
When the program is started (t=0), the FLIPR initially determines
the fluorescence of all wells of the plate a number of times,
before the depolarization is started after about 20 seconds by
addition of sodium ions. In each case, the addition solution is
mixed from the three buffers (wash buffer, sodium buffer and cesium
buffer) such that the addition results in no change of the
osmolarity, or in a change which is identical in all wells. The
measurement of the fluorescence can be terminated after about 5
minutes. The wells to which, in addition to Na.sup.+, 8 mM Cs.sup.+
were added to block the HCN channel completely serve as negative
control. By deducting these values from the others, a good measure
for the activity of the HCN channel under the influence of the
substance to be examined is obtained. For evaluation, the change in
fluorescence in the interval where it is linear and in which
uninhibited HCN2-transfected cells differ significantly from
inhibited cells is examined.
REFERENCES All references disclosed herein, including the following
references, are hereby incorporated herein by reference. Biel M.,
Ludwig A., Zong X., Hofmann R. (1999) Hyperpolarization-activated
cation channels: A multigene family. Rev. Physiol. Biochem.
Pharmacol. 136: 165-181. Hamill O. P., Marty A., Neher E., Sakmann
B., Sigworth F. J. (1981) Improved patch-clamp techniques for
high-resolution current recording from cells and cell-free membrane
patches. Pflugers Arch. 391: 85-100. Ludwig A., Zong X., Jeglitsch
M., Hofmann F., Biel M. (1998) A family of
hyperpolarization-activated mammalian cation channels. Nature 393:
587-591. Ludwig A., Zong X., Stieber J., Hullin R., Hofmann R.,
Biel M. (1999) Two pacemaker channels from heart with profoundly
different activation kinetics. EMBO J. 18: 2323-2329. Reiffen A.,
Eberlein W., Muller P., Psiorz M., Noll K., Heider J., Lillie C.,
Kobinger W., Luger P. (1990) Specific bradycardiac agents. 1.
Chemistry, pharmacology, and structure-activity relationships of
substituted benzazepinones, a new class of compounds exerting
antiischemic properties. J. Med. Chem. 33: 1496-1504.
TABLE 1 SEQ ID NO.1 Protein sequence of huHCN2 Accession number:
AAC28444 1 MDARGGGGRP GESPGASPTT GPPPPPPPRP PKQQPPPPPP PAPPPGPGPA
PPQHPPRAEA 61 LPPEAADEGG PRGRLRSRDS SCGRPGTPGA ASTAKGSPNG
ECGRGEPQCS PAGFEGPARG 121 PKVSFSCRGA ASGPAPGPGP AEEAGSEEAG
PAGEPRGSQA SFMQRQFGAL LQPGVNKFSL 181 RMFGSQKAVE REQERVKSAG
AWIIHPYSDF RFYWDFTMLL FMVGNLIIIP VGITFFKDET 241 TAPWIVFNVV
SDTFFLMDLV LNFRTGIVIE DNTEIILDPE KIKKKYLRTW FVVDFVSSIP 301
VDYIFLIVEK GIDSEVYKTA RALRIVRFTK ILSLLRLLRL SRLIRYIHQW EEIFRMTYDL
361 ASAVMRICNL ISMMLLLCHW DGCLQFLVPM LQDFPRNCWV SINGMVNRSW
SELYSFALFK 421 AMSHMLCIGY GRQAPESMTD IWLTMLSMIV GATCYAMFIG
HATALIQSLD SSRRQYQEKY 481 KQVEQYMSFH KLPADFRQKI HDYYEHRYQG
KMFDEDSILG ELNGPLREEI VNFNCRKLVA 541 SMPLFANADP NFVTAMLTKL
KFEVFQPGDY IIREGTIGKK MYFIQHGVVS VLTKGNKEMK 601 LSDGSYFGEI
CLLTRGRRTA SVRADTYCRL YSLSVDNFNE VLEEYPMMRR AFETVAIDRL 661
DRIGKKNSIL LHKVQHDLNS GVFNNQENAI IQEIVKYDRE MVQQAELGQR VGLFPPPPPP
721 PQVTSAIATL QQAAAMSFCP QVARPLVGPL ALGSPRLVRR PPPGPAPAAA
SPGPPPPASP 781 PGAPASPRAP RTSPYGGLPA APLAGPALPA RRLSRASRPL
SASQPSLPHG APGPAASTRP 841 ASSSTPRLGP TPAARAAAPS PDRRDSASPG
AAGGLDPQDS ARSRLSSNL
TABLE 2 SEQ ID NO.2 Nucleotide sequence of huHCN2 Accession number:
AF065164 1 CGGCTCCGCT CCGCACTGCC CGGCGCCGCC TCGCCATGGA CGCGCGCGGG
GGCGGCGGGC 61 GGCCCGGGGA GAGCCCGGGC GCGAGCCCCA CGACCGGGCC
GCCGCCGCCG CCGCCCCCGC 121 GCCCCCCCAA ACAGCAGCCG CCGCCGCCGC
CGCCGCCCGC GCCCCCCCCG GGCCCCGGGC 181 CCGCGCCCCC CCAGCACCCG
CCCCGGGCCG AGGCGTTGCC CCCGGAGGCG GCGGATGAGG 241 GCGGCCCGCG
GGGCCGGCTC CGCAGCCGCG ACAGCTCGTG CGGCCGCCCC GGCACCCCGG 301
GCGCGGCGAG CACGGCCAAG GGCAGCCCGA ACGGCGAGTG CGGGCGCGGC GAGCCGCAGT
361 GCAGCCCCGC GGGGCCCGAG GGCCCGGCGC GGGGGCCCAA GGTGTCGTTC
TCGTGCCGCG 421 GGGCGGCCTC GGGGCCCGCG CCGGGGCCGG GGCCGGCGGA
GGAGGCGCGC AGCGAGGAGG 481 CGGGCCCGGC GGGGGAGCCG CGCGGCAGCC
AGGCCAGCTT CATGCAGCGC CAGTTCGGCG 541 CGCTCCTGCA GCCGGGCGTC
AACAAGTTCT CGCTGCGGAT GTTCGGCAGC CAGAAGGCCG 601 TGGAGCGCGA
GCAGGAGCGC GTCAAGTCGG CGGGGGCCTG GATCATCCAC CCGTACAGCG 661
ACTTCAGGTT CTACTGGGAC TTCACCATGC TGCTGTTCAT GGTGGGAAAC CTCATCATCA
721 TCCCAGTGGG CATCACCTTC TTCAAGGATG AGACCACTGC CCCGTGGATC
GTGTTCAACG 781 TGGTCTCGGA CACCTTCTTC CTCATGGACC TGGTGTTGAA
CTTCCGCACC GGCATTGTGA 841 TCGAGGACAA CACGGAGATC ATCCTGGACC
CCGAGAAGAT CAAGAAGAAG TATCTGCGCA 901 CGTGGTTCGT GGTGGACTTC
GTGTCCTCCA TCCCCGTGGA CTACATCTTC CTTATCGTGG 961 AGAAGGGCAT
TGACTCCGAG GTCTACAAGA CGGCACGCGC CCTGCGCATC GTGCGCTTCA 1021
CCAAGATCCT CAGCCTCCTG CGGCTGCTGC GCCTCTCACG CCTGATCCGC TACATCCATC
1081 AGTGGGAGGA GATCTTCCAC ATGACCTATG ACCTGGCCAG CGCGGTGATG
AGGATCTGCA 1141 ATCTCATCAG CATGATGCTG CTGCTCTGCC ACTGGGACGG
CTGCCTGCAG TTCCTGGTGC 1201 CTATGCTGCA GGACTTCCCG CGCAACTGCT
GGGTGTCCAT CAATGGCATG GTGAACCACT 1261 CGTGGAGTGA ACTGTACTCC
TTCGCACTCT TCAAGGCCAT GAGCCACATG CTGTGCATCG 1321 GGTACGGCCG
GCAGGCGCCC GAGAGCATGA CGGACATCTG GCTGACCATG CTCAGCATGA 1381
TTGTGGGTGC CACCTGCTAC GCCATGTTCA TCGGCCACGC CACTGCCCTC ATCCAGTCGC
1441 TGGACTCCTC GCGGCGCCAG TACCAGGAGA AGTACAAGCA GGTGGAGCAG
TACATGTCCT 1501 TCCACAAGCT GCCAGCTGAC TTCCGCCAGA AGATCCACGA
CTACTATGAG CACCGTTACC 1561 AGGGCAAGAT GTTTGACGAG GACAGCATCC
TGGGCGAGCT CAACGGGCCC CTGCGGGAGG 1621 AGATCGTCAA CTTCAACTGC
CGGAAGCTGG TGGCCTCCAT GCCGCTGTTC GCCAACGCCG 1681 ACCCCAACTT
CGTCACGGCC ATGCTGACCA AGCTCAAGTT CGAGGTCTTC CAGCCGGGTG 1741
ACTACATCAT CCGCGAAGGC ACCATCGGGA AGAAGATGTA CTTCATCCAG CACGGCGTGG
1801 TCAGCGTGCT CACTAAGGGC AACAAGGAGA TGAAGCTGTC CGATGGCTCC
TACTTCGGGG 1861 AGATCTGCCT GCTCACCCGG GGCCGCCGCA CGGCGAGCGT
GCGGGCTGAC ACCTACTGCC 1921 GCCTCTATTC GCTGAGCGTG GACAACTTCA
ACGAGGTGCT GGAGGAGTAC CCCATGATGC 1981 GGCGCGCCTT CGAGACGGTG
GCCATCGACC GCCTGGACCG CATCGGCAAG AAGAATTCCA 2041 TCCTCCTGCA
CAAGGTGCAG CATGACCTCA ACTCGGGCGT ATTCAACAAC CAGGAGAACG 2101
CCATCATCCA GGAGATCGTC AAGTACGACC GCGAGATGGT GCAGCAGGCC GAGCTGGGTC
2161 AGCGCGTGGG CCTCTTCCCG CCGCCGCCGC CGCCGCCGCA GGTCACCTCG
GCCATCGCCA 2221 CGCTGCAGCA GGCGGCGGCC ATGAGCTTCT GCCCGCAGGT
GGCGCGGCCG CTCGTGGGGC 2281 CGCTGGCGCT CGGCTCGCCG CGCCTCGTGC
GCCGCCCGCC CCCGGGGCCC GCACCTGCCG 2341 CCGCCTCACC CGGGCCCCCG
CCCCCCGCCA GCCCCCCGGG CGCGCCCGCC AGCCCCCGGG 2401 CACCGCGGAC
CTCGCCCTAC GGCGGCCTGC CCGCCGCCCC CCTTGCTGGG CCCGCCCTGC 2461
CCGCGCGCCG CCTGAGCCGC GCGTCGCGCC CACTGTCCGC CTCGCAGCCC TCGCTGCCTC
2521 ACGGCGCCCC CGGCCCCGCG GCCTCCACAC GCCCGGCCAG CAGCTCCACA
CCGCGCTTGG 2581 GGCCCACGCC CGCTGCCCGG GCCGCCGCGC CCAGCCCGGA
CCGCAGGGAC TCGGCCTCAC 2641 CCGGCGCCGC CGGCGGCCTG GACCCCCAGG
ACTCCGCGCG CTCGCGCCTC TCGTCCAACT 2701 TGTGACCCTC GCCGACCGCC
CCGCGGGCCC AGGCGGGCCG GGGGCGGGGC CGTCATCCAG 2761 ACCAAAGCCA
TGCCATTGCG CTGCCCCGGC CGCCAGTCCG CCCAGAAGCC ATAGACGAGA 2821
CGTAGGTAGC CGTAGTTGGA CGGACGGGCA GGGCCGGCGG GGCAGCCCCC TCCGCGCCCC
2881 CGGCCGTCCC CCCTCATCGC CCCGCGCCCA CCCCCATCGC CCCTGCCCCC
GGCGGCGGCC 2941 TCGCGTGCGA GGGGGCTCCC TTCACCTCGG TGCCTCAGTT
CCCCCAGCTC TAAGACAGGG 3001 ACGGGGCGGC CCAGTGGCTG AGAGGAGCCG
GCTGTGGAGC CCCGCCCGCC CCCCACCCTC 3061 TAGGTGGCCC CCGTCCGAGG
AGGATCGTTT TCTAAGTGCA ATACTTGGCC CGCCGGCTTC 3121 CCGCTGCCCC
CATCGCGCTC ACGCAATAAC CGGCCCGGCC CCCGTCCGCG CGCGTCCCCC 3181
GGTGACCTCG GGGAGCAGCA CCCCGCCTCC CTCCAGCACT GGCACCGAGA GGCAGGCCTG
3241 GCTGCGCAGG GCGCGGGGGG GAGGCTGGGG TCCCGCCGCC GTGATGAATG
TACTGACGAG 3301 CCGAGGCAGC AGTGCCCCCA CCGTGGCCCC CCACGCCCCA
TTAACCCCCA CACCCCCATT 3361 CCGCGCAATA AA
TABLE 3 SEQ ID NO.3 Protein sequence of huHCN4 Accession number:
HSA132429 1 MDKLPPSMRK RLYSLPQQVG AKAWIMDEEE DAEEEGAGGR QDPSRRSIRL
51 RPLPSPSPSA AAGGTESRSS ALGAADSEGP ARGAGKSSTN GDCRRFRGSL 101
ASLGSRGGGS GGTGSGSSHG HLHDSAEERR LIAEGDASPG EDRTPPGLAA 151
EPERPGASAQ PAASPPPPQQ PPQPASASCE QPSVDTAIKV EGGAAAGDQI 201
LPEAEVRLGQ AGFMQRQFGA MLQPGVNKFS LRMFGSQKAV EREQERVKSA 251
GFWIIHPYSD FRFYWDLTML LLMVGNLIII PVGITFFKDE NTTPWIVFNV 301
VSDTFFLIDL VLNFRTGIVV EDNTEIILDP QRIKMKYLKS WFMVDFISSI 351
PVDYIFLIVE TRIDSEVYKT ARALRIVRFT KILSLLRLLR LSRLIRYIHQ 401
WEEIFHMTYD LASAVVRIVN LIGMMLLLCH WDGCLQFLVP MLQDFPDDCW 451
VSINNMVNNS WGKQYSYALF KAMSHMLCIG YGRQAPVGMS DVWLTMLSMI 501
VGATCYAMFI GHATALIQSL DSSRRQYQEK YKQVEQYMSF HKLPPDTRQR 551
IHDYYEHRYQ GKMFDEESIL GELSEPLREE IINFNCRKLV ASMPLFANAD 601
PNFVTSMLTK LRFEVFQPGD YIIREGTIGK KMYFIQHGVV SVLTKGNKET 651
KLADGSYFGE ICLLTRGRRT ASVRADTYCR LYSLSVDNFN EVLEEYPMMR 701
RAFETVALDR LDRIGKKNSI LLHKVQHDLN SGVFNYQENE IIQQIVQHDR 751
EMAHCAHRVQ AAASATPTPT PVIWTPLIQA PLQAAAATTS VAIALTHHPR 801
LPAAIFRPPP GSGLGNLGAG QTPRHLKRLQ SLIPSALGSA SPASSPSQVD 851
TPSSSSFHIQ QLAGFSAPAG LSPLLPSSSS SPPPGACGSP SAPTPSAGVA 901
ATTIAGFGHF HKALGGSLSS SDSPLLTPLQ PGARSPQAAQ PSPAPPGARG 951
GLGLPEHFLP PPPSSRSPSS SPGQLGQPPG ELSLGLATGP LSTPETPPRQ 1001
PEPPSLVAGA SGGASPVGFT PRGGLSPPGH SPGPPRTFPS APPRASGSHG 1051
SLLLPPASSP PPPQVPQRRG TPPLTPGRLT QDLKLISASQ PALPQDGAQT 1101
LRRASPHSSG ESMAAFPLFP RAGGGSGGSG SSGGLGPPGR PYGAIPGQHV 1151
TLPRKTSSGS LPPPLSLFGA RATSSGGPPL TAGPQREPGA RPEPVRSKLP 1201
SNL*
TABLE 4 SEQ ID NO.4 Nucleotide sequence of huHCN4 Accession number:
HSA132429 1 GGTCGCTGGG CTCCGCTCGG TTGCGGCGGG AGCCCCGGGA CGGGCCGGAC
GGGCCGGGGC 61 AGAGGAGGCG AGGCGAGCTC GCGGGTGGCC AGCCACAAAG
CCCGGGCGGC GAGACAGACG 121 GACAGCCAGC CCTCCCGCGG GACGCACGCC
CGGGACCCGC GCGGGCCGTG CGCTCTGCAC 181 TCCGGAGCGG TTCCCTGAGC
GCCGCGGCCG CAGAGCCTCT CCGGCCGGCG CCCATTGTTC 241 CCCGCGGGGG
CGGGGCGCCT GGAGCCGGGC GGCGCGCCGC GCCCCTGAAC GCCAGAGGGA 301
GGGAGGGAGG CAAGAAGGGA GCGCGGGGTC CCCGCGCCCA GCCGGGCCCG GGAGGAGGTG
361 TAGCGCGGCG AGCCCGGGGA CTCGGAGCGG GACTAGGATC CTCCCCGCGG
CGCGCAGCCT 421 GCCCAAGCAT GGGCGCCTGA GGCTGCCCCC ACGCCGGCGG
CAAAGGACGC GTCCCCACGG 481 GCGGACTGAC CGGCGGGCGG ACCTGGAGCC
CGTCCGCGGC GCCGCGCTCC TGCCCCCGGC 541 CCGGTCCGAC CCCGGCCCCT
GGCGCCATGG ACAAGCTGCC GCCGTCCATG CGCAAGCGGC 601 TCTACAGCCT
CCCGCAGCAG GTGGGGGCCA AGGCGTGGAT CATGGACGAG GAAGAGGACG 661
CCGAGGAGGA GGGGGCCGGG GGCCGCCAAG ACCCCAGCCG CAGGAGCATC CGGCTGCGGC
721 CACTGCCCTC GCCCTCCCCC TCGGCGGCCG CGGGTGGCAC GGAGTCCCGG
AGCTCGGCCC 781 TCGGGGCAGC GGACAGCGAA GGGCCGGCCC GCGGCGCGGG
CAAGTCCAGC ACGAACGGCG 841 ACTGCAGGCG CTTCCGCGGG AGCCTGGCCT
CGCTGGGCAG CCGGGGCGGC GGCAGCGGCG 901 GCACGGGGAG CGGCAGCAGT
CACGGACACC TGCATGACTC CGCGGAGGAG CGGCGGCTCA 961 TCGCCGAGGG
CGACGCGTCC CCCGGCGAGG ACAGGACGCC CCCAGGCCTG GCGGCCGAGC 1021
CCGAGCGCCC CGGCGCCTCG GCGCAGCCCG CAGCCTCGCC GCCGCCGCCC CAGCAGCCAC
1081 CGCAGCCGGC CTCCGCCTCC TGCGAGCAGC CCTCGGTGGA CACCGCTATC
AAAGTGGAGG 1141 GAGGCGCGGC TGCCGGCGAC CAGATCCTCC CGGAGGCCGA
GGTGCGCCTG GGCCAGGCCG 1201 GCTTCATGCA GCGCCAGTTC GGGGCCATGC
TCCAACCCGG GGTCAACAAA TTCTCCCTAA 1261 GGATGTTCGG CAGCCAGAAA
GCCGTGGAGC GCGAACAGGA GAGGGTCAAG TCGGCCGGAT 1321 TTTGGATTAT
CCACCCCTAC AGTGACTTCA GATTTTACTG GGACCTGACC ATGCTGCTGC 1381
TGATGGTGGG AAACCTGATT ATCATTCCTG TGGGCATCAC CTTCTTCAAG GATGAGAACA
1441 CCACACCCTG GATTGTCTTC AATGTGGTGT CAGACACATT CTTCCTCATC
GACTTGGTCC 1501 TCAACTTCCG CACAGGGATC GTGGTGGAGG ACAACACAGA
GATCATCCTG GACCCGCAGC 1561 GGATTAAAAT GAAGTACCTG AAAAGCTGGT
TCATGGTAGA TTTCATTTCC TCCATCCCCG 1621 TGGACTACAT CTTCCTCATT
GTGGAGACAC GCATCGACTC GGAGGTCTAC AAGACTGCCC 1681 GGGCCCTGCG
CATTGTCCGC TTCACGAAGA TCCTCAGCCT CTTACGCCTG TTACGCCTCT 1741
CCCGCCTCAT TCGATATATT CACCAGTGGG AAGAGATCTT CCACATGACC TACGACCTGG
1801 CCAGCGCCGT GGTGCGCATC GTGAACCTCA TCGGCATGAT GCTCCTGCTC
TGCCACTGGG 1861 ACGGCTGCCT GCAGTTCCTG GTACCCATGC TACAGGACTT
CCCTGACGAC TGCTGGGTGT 1921 CCATCAACAA CATGGTGAAC AACTCCTGGG
GGAAGCAGTA CTCCTACGCG CTCTTCAAGG 1981 CCATGAGCCA CATGCTGTGC
ATCGGCTACG GGCGGCAGGC GCCCGTGGGC ATGTCCGACG 2041 TCTGGCTCAC
CATGCTCAGC ATGATCGTGG GTGCCACCTG CTACGCCATG TTCATTGGCC 2101
ACGCCACTGC CCTCATCCAG TCCCTGGACT CCTCCCGGCG CCAGTACCAG CAAAAGTACA
2161 AGCAGGTGGA GCAGTACATG TCCTTTCACA AGCTCCCGCC CGACACCCGG
CAGCGCATCC 2221 ACGACTACTA CGAGCACCGC TACCAGGGCA AGATGTTCGA
CGAGGAGAGC ATCCTGGGCG 2281 AGCTAAGCGA GCCCCTGCGG GAGGAGATCA
TCAACTTTAA CTGTCGGAAG CTGGTGGCCT 2341 CCATGCCACT GTTTGCCAAT
GCGGACCCCA ACTTCGTGAC GTCCATGCTG ACCAAGCTGC 2401 GTTTCGAGGT
CTTCCAGCCT GGGGACTACA TCATCCGGGA AGGCACCATT GGCAAGAAGA 2461
TGTACTTCAT CCAGCATGGC GTGGTCAGCG TGCTCACCAA GGGCAACAAG GAGACCAAGC
2521 TGGCCGACGG CTCCTACTTT GGAGAGATCT GCCTGCTGAC CCGGGGCCGG
CGCACAGCCA 2581 GCGTGAGGGC CGACACCTAC TGCCGCCTCT ACTCGCTGAG
CGTGGACAAC TTCAATGAGG 2641 TGCTGGAGGA GTACCCCATG ATGCGAAGGG
CCTTCGAGAC CGTGGCGCTG GACCGCCTGG 2701 ACCGCATTGG CAAGAAGAAC
TCCATCCTCC TCCACAAAGT CCAGCACGAC CTCAACTCCG 2761 GCGTCTTCAA
CTACCAGGAG AATGAGATCA TCCAGCAGAT TGTGCAGCAT GACCGGGAGA 2821
TGGCCCACTG CGCGCACCGC GTCCAGGCTG CTGCCTCTGC CACCCCAACC CCCACGCCCG
2881 TCATCTGGAC CCCGCTGATC CAGGCACCAC TGCAGGCTGC CGCTGCCACC
ACTTCTGTGG 2941 CCATAGCCCT CACCCACCAC CCTCGCCTGC CTGCTGCCAT
CTTCCGCCCT CCCCCAGGAT 3001 CTGGGCTGGG CAACCTCGGT GCCGGGCAGA
CGCCAAGGCA CCTGAAACGG CTGCAGTCCC 3061 TGATCCCTTC TGCGCTGGGC
TCCGCCTCGC CCGCCAGCAG CCCGTCCCAG GTGGACACAC 3121 CGTCTTCATC
CTCCTTCCAC ATCCAACAGC TGGCTGGATT CTCTGCCCCC GCTGGACTGA 3181
GCCCACTCCT GCCCTCATCC AGCTCCTCCC CACCCCCCGG GGCCTGTGGC TCCCCCTCGG
3241 CTCCCACACC ATCAGCTGGC GTAGCCGCCA CCACCATAGC CGGGTTTGGC
CACTTCCACA 3301 AGGCGCTGGG TGGCTCCCTG TCCTCCTCCG ACTCTCCCCT
GCTCACCCCG CTGCAGCCAG 3361 GCGCCCGCTC CCCGCAGGCT GCCCAGCCAT
CTCCCGCGCC ACCCGGGGCC CGGGGAGGCC 3421 TGGGACTCCC GGAGCACTTC
CTGCCACCCC CACCCTCATC CAGATCCCCG TCATCTAGCC 3481 CCGGGCAGCT
GGGCCAGCCT CCCGGGGAGT TGTCCCTAGG TCTGGCCACT GGCCCACTGA 3541
GCACGCCAGA GACACCCCCA CGGCAGCCTG AGCCGCCGTC CCTTGTGGCA GGGGCCTCTG
3601 GGGGGGCTTC CCCTGTAGGC TTTACTCCCC GAGGAGGTCT CAGCCCCCCT
GGCCACAGCC 3661 CAGGCCCCCC AAGAACCTTC CCGAGTGCCC CGCCCCGGGC
CTCTGGCTCC CACGGATCCT 3721 TGCTCCTGCC ACCTGCATCC AGCCCCCCAC
CACCCCAGGT CCCCCAGCGC CGGGGCACAC 3781 CCCCGCTCAC CCCCGGCCGC
CTCACCCAGG ACCTCAAGCT CATCTCCGCG TCTCAGCCAG 3841 CCCTGCCTCA
GGACGGGGCG CAGACTCTCC GCAGAGCCTC CCCGCACTCC TCAGGGGAGT 3901
CCATGGCTGC CTTCCCGCTC TTCCCCAGGG CTGGGGGTGG CAGCGGGGGC AGTGGGAGCA
3961 GCGGGGGCCT CGGTCCCCCT GGGAGGCCCT ATGGTGCCAT CCCCGGCCAG
CACGTCACTC 4021 TGCCTCGGAA GACATCCTCA GGTTCTTTGC CACCCCCTCT
GTCTTTGTTT GGGGCAAGAG 4081 CCACCTCTTC TGGGGGGCCC CCTCTGACTG
CTGGACCCCA GAGGGAACCT GGGGCCAGGC 4141 CTGAGCCAGT GCGCTCCAAA
CTGCCATCCA ATCTATGAGC TGGGCCCTTC CTTCCCTCTT 4201 CTTTCTTCTT
TTCTCTCCCT TCCTTCTTCC TTCAGGTTTA ACTGTGATTA GGAGATATAC 4261
CAATAACAGT AATAATTATT TAAAAAACCA CACACACCAG AAAAACAAAA GACAGCAGAA
4321 AATAACCAGG TATTCTTAGA GCTATAGATT TTTGGTCACT TGCTTTTATA
GACTATTTTA 4381 ATACTCAGCA CTAGAGGGAG GGAGGGGGAG GGAGGAGGGA
GCAGGCAGGT CCCAAATGCA 4441 AAAGCCAGAG AAAGGCAGAT GGGGTCTCCG
GGGCTGGGCA GGGGTGGGAG TGGCCAGTGT 4501 TGGCGGTTCT TAGAGCAGAT
GTGTCATTGT GTTCATTTAG AGAAACAGCT GCCATCAGCC 4561 CGTTAGCTGT
AACTTGGAGC TCCACTCTGC CCCCAGAAAG GGGCTGCCCT GGGGTGTGCC 4621
CTGGGGAGCC TCAGAAGCCT GCGACCTTGG GAGAAAAGGG CCAGGGCCCT GAGGGCCTAG
4681 CATTTTTTCT ACTGTAAACG TAGCAAGATC TGTATATGAA TATGTATATG
TATATGTATG 4741 TAAGATGTGT ATATGTATAG CTATGTAGCG CTCTGTAGAG
CCATGTAGAT AGCCACTCAC 4801 ATGTGCGCAC ACGTGTGCGG TCTAGTTTAA
TCCCATGTTG ACAGGATGCC CAGGTCACCT 4861 TACACCCAGC AACCCGCCTT
GGCCCGCAGG CTGTGCACTG CATGGTCTAG GGACGTTCTC 4921 TCTCCAGTCC
TCAGGGAAGA GGACGCCAGG ACTTCGCAGC AGGCCCCCTC TCTCCCCATC 4981
TCTGGTCTCA AAGCCAGTCC CAGCCTGACC TCTCACCACA CGGAAGTGGA AGACTCCCCT
5041 TTCCTAGGGC CTCAAGCACA CACCG
TABLE 5 SEQ ID NO.5 Protein sequence of muHCN2 Accession number:
CAA12406 1 MDARGGGGRP GDSPGTTPAP GPPPPPPPPA PPQPQPPPAP PPNPTTPSHP
ESADEPGPRA 61 RLCSRDSACT PGAAKGGANG ECGRGEPQCS PEGPARGPKV
SFSCRGAASG PSAAEEAGSE 121 EAGPAGEPRG SQASFLQRQF GALLQPGVNK
FSLRMFGSQK AVEREQERVK SAGAWIIHPY 181 SDFRFYWDFT MLLFMVGNLI
IIPVGITFFK DETTAPWIVF NVVSDTFFLM DLVLNFRTGI 241 VIEDNTEIIL
DPEKIKKKYL RTWFVVDFVS SIPVDYIFLI VEKGIDSEVY KTARALRIVR 301
FTKILSLLRL LRLSRLIRYI HQWEEIFHMT YDLASAVMRI CNLISMMLLL CHWDGCLQFL
361 VPMLQDFPSD CWVSINNMVN HSWSELYSFA LFKAMSHMLC IGYGRQAPES
MTDIWLTMLS 421 MIVGATCYAM FIGHATALIQ SLDSSRRQYQ EKYKQVEQYM
SFHKLPADFR QKIHDYYEHR 481 YQGKMFDEDS ILGELNGPLR EEIVNFNCRK
LVASMPLFAN ADPNFVTAML TKLKFEVFQP 541 GDYIIREGTI GKKMYFIQHG
VVSVLTKGNK EMKLSDGSYF GEICLLTRGR RTASVRADTY 601 CRLYSLSVDN
FNEVLEEYPM MRRAFETVAI DRLDRIGKKN SILLHKVQHD LSSGVFNNQE 661
NAIIQEIVKY DREMVQQAEL GQRVGLFPPP PPPQVTSAIA TLQQAVAMSF CPQVARPLVG
721 PLALGSPRLV RRAPPGPLPP AASPGPPAAS PPAAPSSPRA PRTSPYGVPG
SPATRVGPAL 781 PARRLSRASR PLSASQPSLP HGVPAPSPAA SARPASSSTP
RLGPAPTART AAPSPDRRDS 841 ASPGAASGLD PLDSARSRLS SNL
TABLE 6 SEQ ID NO. 6 Nucleotide sequence of muHCN2 Accession
number: MMJ225122 1 CCGCTCCGCT CCGCACTGCC CGGCGCCGCC TCGCCATGGA
TGCGCGCGGG GGCGGCGGGC 61 GGCCGGGCGA TAGTCCGGGC ACGACCCCTG
CGCCGGGGCC GCCGCCACCG CCGCCGCCGC 121 CCGCGCCCCC TCAGCCTCAG
CCACCACCCG CGCCACCCCC GAACCCCACG ACCCCCTCGC 181 ACCCGGAGTC
GGCGGACGAG CCCGGCCCGC GCGCCCGGCT CTGCAGCCGC GACAGCGCCT 241
GCACCCCTGG CGCGGCCAAG GGCGGCGCGA ATGGCGAGTG CGGGCGCGGG GAGCCGCAGT
301 GCAGCCCCGA GGGCCCCGCG CGCGGCCCCA AGGTTTCGTT CTCATGCCGC
GGGGCGGCCT 361 CCGGGCCCTC GGCGGCCGAG GAGGCGGGCA GCGAGGAGGC
GGGCCCGGCG GGTGAGCCGC 421 GCGGCAGCCA GGCTAGCTTC CTGCAGCGCC
AATTCGGGGC GCTTCTGCAG CCCGGCGTCA 481 ACAAGTTCTC CCTGCGGATC
TTCGGCAGCC AGAAGGCCGT GGAGCGCGAG CAGGAACGCG 541 TGAAGTCGGC
GGGGGCCTGG ATCATCCACC CCTACAGCGA CTTCAGGTTC TACTGGGACT 601
TCACCATGCT GTTGTTCATG GTGGGAAATC TCATTATCAT TCCCGTGGGC ATCACTTTCT
661 TCAAGGACGA GACCACCGCG CCCTGGATCG TCTTCAACGT GGTCTCGGAC
ACTTTCTTCC 721 TCATGGACTT GGTGTTGAAC TTCCGCACCG GCATTGTTAT
TGAGGACAAC ACGGAGATCA 781 TCCTGGACCC CGAGAAGATA AAGAAGAAGT
ACTTGCGTAC GTGGTTCGTG GTGGACTTCG 841 TGTCATCCAT CCCGGTGGAC
TACATCTTCC TCATAGTGGA GAAGGGAATC GACTCCGAGG 901 TCTACAAGAC
AGCGCGTGCT CTGCGCATCG TGCGCTTCAC CAAGATCCTC AGTCTGCTGC 961
GGCTGCTGCG GCTATCACGG CTCATCCGAT ATATCCACCA GTGGGAAGAG ATTTTCCACA
1021 TGACCTACGA CCTGGCAAGT GCAGTGATGC GCATCTGTAA CCTGATCAGC
ATGATGCTAC 1081 TGCTCTGCCA CTGGGACGGT TGCCTGCAGT TCCTGGTGCC
CATGCTGCAA GACTTCCCCA 1141 GCGACTGCTG GGTGTCCATC AACAACATGG
TGAACCACTC GTGGAGCGAG CTCTACTCGT 1201 TCGCGCTCTT CAAGGCCATG
AGCCACATGC TGTGCATCGG CTACGGGCGG CAGGCGCCCG 1261 AGAGCATGAC
AGACATCTGG CTGACCATGC TCAGCATGAT CGTAGGCGCC ACCTGCTATG 1321
CCATGTTCAT TGGGCACGCC ACTGCGCTCA TCCAGTCCCT GGATTCGTCA CGGCGCCAAT
1381 ACCAGGAGAA GTACAAGCAA GTAGAGCAAT ACATGTCCTT CCACAAACTG
CCCGCTGACT 1441 TCCGCCAGAA GATCCACGAT TACTATGAAC ACCGGTACCA
AGGGAAGATG TTTGATGAGG 1501 ACAGCATCCT TGGGGAACTC AACGGGCCAC
TGCGTGAGGA GATTGTGAAC TTCAACTGCC 1561 GGAAGCTGGT GGCTTCCATG
CCGCTGTTTG CCAATGCAGA CCCCAACTTC GTCACAGCCA 1621 TGCTGACAAA
GCTCAAATTT GAGGTCTTCC AGCCTGGAGA TTACATCATC CGAGAGGGGA 1681
CCATCGGGAA GAAGATGTAC TTCATCCAGC ATGGGGTGGT GAGCGTGCTC ACCAAGGGCA
1741 ACAAGGAGAT GAAGCTGTCG GATGGCTCCT ATTTCGGGGA GATCTGCTTG
CTCACGAGGG 1801 GCCGGCGTAC GGCCAGCGTG CGAGCTGACA CCTACTGTCG
CCTCTACTCA CTGAGTGTGG 1861 ACAATTTCAA CGAGGTGCTG GAGGAATACC
CCATGATGCG GCGTGCCTTT GAGACTGTGG 1921 CTATTGACCG GCTAGATCGC
ATAGGCAAGA AGAACTCCAT CTTGCTGCAC AAGGTTCAGC 1981 ATGATCTCAG
CTCAGGTGTG TTCAACAACC AGGAGAATGC CATCATCCAG GAGATTGTCA 2041
AATATGACCG TGAGATGGTG CAGCAGGCAG AGCTTGGCCA GCGTGTGGGG CTCTTCCCAC
2101 CACCGCCACC ACCGCAGGTC ACATCGGCCA TTGCCACCCT ACAGCAGGCT
GTGGCCATGA 2161 GCTTCTGCCC GCAGGTGGCC CGCCCGCTCG TGGGGCCCCT
GGCGCTAGGC TCCCCACGCC 2221 TAGTGCGCCG CGCGCCCCCA GGGCCTCTGC
CTCCTGCAGC CTCGCCAGGG CCACCCGCAG 2281 CAAGCCCCCC GGCTGCACCC
TCGAGCCCTC GGGCACCGCG GACCTCACCC TACGGTGTGC 2341 CTGGCTCTCC
GGCAACGCGC GTGGGGCCCG CATTGCCCGC ACGTCGCCTG AGCCGCGCCT 2401
CGCGCCCACT GTCCGCCTCG CAGCCCTCGC TGCCCCATGG CGTGCCCGCG CCCAGCCCCG
2461 CGGCCTCTGC GCGCCCGGCC AGCAGCTCCA CGCCGCGCCT GGGACCCGCA
CCCACCGCCC 2521 GGACCGCCGC GCCCAGTCCG GACCGCAGGG ACTCAGCCTC
GCCGGGCGCT GCCAGTGGCC 2581 TCGACCCACT GGACTCTGCG CGCTCGCGCC
TCTCTTCCAA CTTGTGACCC TTGAGCGCCG 2641 CCCCGCGGGC CGGGCGGGGC
CGTCATCCAC ACCAAAGCCA TGCCTCGCGC CGCCCGCCCG 2701 TGCCCGTGCA
GAAGCCATAG AGGGACGTAG GTAGCTTAGG AGGCGGGCGG CCCTGCGCCC 2761
GGCTGTCCCC CCATCGCCCT GCGCCCACCC CCATCGCCCC TGCCCCAGCG GCGGCCGCAC
2821 GGGAGAGGGA GGGGTGCGAT CACCTCGGTG CCTCAGCCCC AACCTGGGAC
AGGGACAGGG 2881 CGGCCCTGGC CGAGGACCTG GCTGTGCCCC GCATGTGCGG
TGGCCTCCGA GGAAGAATAT 2941 GGATCAAGTG CAATACACGG CCAAGCCGGC
GTGGGGGTGA GGCTGGGTCC CCGGCCGTCG 3001 CCATGAATGT ACTGACGAGC
CGAGGCAGCA GTGGCCCCCA CGCCCCATTA ACCCACAACC 3061 CCATTCCGCG
CAATAAACGA CAGCATTGGC AAAAAAAAAA AA //
TABLE 7 Abbreviations AKT Arabidopsis thaliana K+ transport cAMP
cyclic adenosine monophosphate CHO Chinese hamster ovary EDTA
ethylenediamine tetraacetic acid FLIPR fluorescence imaging plate
reader HAC hyperpolarization-activated cation channel; this name
was used by some groups HCN hyperpolarization-activated cyclic
nucleotide gated cation channel; this is the new, generally
accepted term HEK human embryonic kidney; HEPES
N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid HTS
high-thoughput screening KAT K+ channel from Arabidopsis
thaliana
SEQUENCE LISTING <100> GENERAL INFORMATION: <160>
NUMBER OF SEQ ID NOS: 10 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 1 <211> LENGTH: 889 <212> TYPE:
PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 1 Met
Asp Ala Arg Gly Gly Gly Gly Arg Pro Gly Glu Ser Pro Gly Ala 1 5 10
15 Ser Pro Thr Thr Gly Pro Pro Pro Pro Pro Pro Pro Arg Pro Pro Lys
20 25 30 Gln Gln Pro Pro Pro Pro Pro Pro Pro Ala Pro Pro Pro Gly
Pro Gly 35 40 45 Pro Ala Pro Pro Gln His Pro Pro Arg Ala Glu Ala
Leu Pro Pro Glu 50 55 60 Ala Ala Asp Glu Gly Gly Pro Arg Gly Arg
Leu Arg Ser Arg Asp Ser 65 70 75 80 Ser Cys Gly Arg Pro Gly Thr Pro
Gly Ala Ala Ser Thr Ala Lys Gly 85 90 95 Ser Pro Asn Gly Glu Cys
Gly Arg Gly Glu Pro Gln Cys Ser Pro Ala 100 105 110 Gly Pro Glu Gly
Pro Ala Arg Gly Pro Lys Val Ser Phe Ser Cys Arg 115 120 125 Gly Ala
Ala Ser Gly Pro Ala Pro Gly Pro Gly Pro Ala Glu Glu Ala 130 135 140
Gly Ser Glu Glu Ala Gly Pro Ala Gly Glu Pro Arg Gly Ser Gln Ala 145
150 155 160 Ser Phe Met Gln Arg Gln Phe Gly Ala Leu Leu Gln Pro Gly
Val Asn 165 170 175 Lys Phe Ser Leu Arg Met Phe Gly Ser Gln Lys Ala
Val Glu Arg Glu 180 185 190 Gln Glu Arg Val Lys Ser Ala Gly Ala Trp
Ile Ile His Pro Tyr Ser 195 200 205 Asp Phe Arg Phe Tyr Trp Asp Phe
Thr Met Leu Leu Phe Met Val Gly 210 215 220 Asn Leu Ile Ile Ile Pro
Val Gly Ile Thr Phe Phe Lys Asp Glu Thr 225 230 235 240 Thr Ala Pro
Trp Ile Val Phe Asn Val Val Ser Asp Thr Phe Phe Leu 245 250 255 Met
Asp Leu Val Leu Asn Phe Arg Thr Gly Ile Val Ile Glu Asp Asn 260 265
270 Thr Glu Ile Ile Leu Asp Pro Glu Lys Ile Lys Lys Lys Tyr Leu Arg
275 280 285 Thr Trp Phe Val Val Asp Phe Val Ser Ser Ile Pro Val Asp
Tyr Ile 290 295 300 Phe Leu Ile Val Glu Lys Gly Ile Asp Ser Glu Val
Tyr Lys Thr Ala 305 310 315 320 Arg Ala Leu Arg Ile Val Arg Phe Thr
Lys Ile Leu Ser Leu Leu Arg 325 330 335 Leu Leu Arg Leu Ser Arg Leu
Ile Arg Tyr Ile His Gln Trp Glu Glu 340 345 350 Ile Phe His Met Thr
Tyr Asp Leu Ala Ser Ala Val Met Arg Ile Cys 355 360 365 Asn Leu Ile
Ser Met Met Leu Leu Leu Cys His Trp Asp Gly Cys Leu 370 375 380 Gln
Phe Leu Val Pro Met Leu Gln Asp Phe Pro Arg Asn Cys Trp Val 385 390
395 400 Ser Ile Asn Gly Met Val Asn His Ser Trp Ser Glu Leu Tyr Ser
Phe 405 410 415 Ala Leu Phe Lys Ala Met Ser His Met Leu Cys Ile Gly
Tyr Gly Arg 420 425 430 Gln Ala Pro Glu Ser Met Thr Asp Ile Trp Leu
Thr Met Leu Ser Met 435 440 445 Ile Val Gly Ala Thr Cys Tyr Ala Met
Phe Ile Gly His Ala Thr Ala 450 455 460 Leu Ile Gln Ser Leu Asp Ser
Ser Arg Arg Gln Tyr Gln Glu Lys Tyr 465 470 475 480 Lys Gln Val Glu
Gln Tyr Met Ser Phe His Lys Leu Pro Ala Asp Phe 485 490 495 Arg Gln
Lys Ile His Asp Tyr Tyr Glu His Arg Tyr Gln Gly Lys Met 500 505 510
Phe Asp Glu Asp Ser Ile Leu Gly Glu Leu Asn Gly Pro Leu Arg Glu 515
520 525 Glu Ile Val Asn Phe Asn Cys Arg Lys Leu Val Ala Ser Met Pro
Leu 530 535 540 Phe Ala Asn Ala Asp Pro Asn Phe Val Thr Ala Met Leu
Thr Lys Leu 545 550 555 560 Lys Phe Glu Val Phe Gln Pro Gly Asp Tyr
Ile Ile Arg Glu Gly Thr 565 570 575 Ile Gly Lys Lys Met Tyr Phe Ile
Gln His Gly Val Val Ser Val Leu 580 585 590 Thr Lys Gly Asn Lys Glu
Met Lys Leu Ser Asp Gly Ser Tyr Phe Gly 595 600 605 Glu Ile Cys Leu
Leu Thr Arg Gly Arg Arg Thr Ala Ser Val Arg Ala 610 615 620 Asp Thr
Tyr Cys Arg Leu Tyr Ser Leu Ser Val Asp Asn Phe Asn Glu 625 630 635
640 Val Leu Glu Glu Tyr Pro Met Met Arg Arg Ala Phe Glu Thr Val Ala
645 650 655 Ile Asp Arg Leu Asp Arg Ile Gly Lys Lys Asn Ser Ile Leu
Leu His 660 665 670 Lys Val Gln His Asp Leu Asn Ser Gly Val Phe Asn
Asn Gln Glu Asn 675 680 685 Ala Ile Ile Gln Glu Ile Val Lys Tyr Asp
Arg Glu Met Val Gln Gln 690 695 700 Ala Glu Leu Gly Gln Arg Val Gly
Leu Phe Pro Pro Pro Pro Pro Pro 705 710 715 720 Pro Gln Val Thr Ser
Ala Ile Ala Thr Leu Gln Gln Ala Ala Ala Met 725 730 735 Ser Phe Cys
Pro Gln Val Ala Arg Pro Leu Val Gly Pro Leu Ala Leu 740 745 750 Gly
Ser Pro Arg Leu Val Arg Arg Pro Pro Pro Gly Pro Ala Pro Ala 755 760
765 Ala Ala Ser Pro Gly Pro Pro Pro Pro Ala Ser Pro Pro Gly Ala Pro
770 775 780 Ala Ser Pro Arg Ala Pro Arg Thr Ser Pro Tyr Gly Gly Leu
Pro Ala 785 790 795 800 Ala Pro Leu Ala Gly Pro Ala Leu Pro Ala Arg
Arg Leu Ser Arg Ala 805 810 815 Ser Arg Pro Leu Ser Ala Ser Gln Pro
Ser Leu Pro His Gly Ala Pro 820 825 830 Gly Pro Ala Ala Ser Thr Arg
Pro Ala Ser Ser Ser Thr Pro Arg Leu 835 840 845 Gly Pro Thr Pro Ala
Ala Arg Ala Ala Ala Pro Ser Pro Asp Arg Arg 850 855 860 Asp Ser Ala
Ser Pro Gly Ala Ala Gly Gly Leu Asp Pro Gln Asp Ser 865 870 875 880
Ala Arg Ser Arg Leu Ser Ser Asn Leu 885 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 2 <211> LENGTH: 3372
<212> TYPE: DNA <213> ORGANISM: Homo sapiens
<400> SEQUENCE: 2 cggctccgct ccgcactgcc cggcgccgcc tcgccatgga
cgcgcgcggg ggcggcgggc 60 ggcccgggga gagcccgggc gcgagcccca
cgaccgggcc gccgccgccg ccgcccccgc 120 gcccccccaa acagcagccg
ccgccgccgc cgccgcccgc gccccccccg ggccccgggc 180 ccgcgccccc
ccagcacccg ccccgggccg aggcgttgcc cccggaggcg gcggatgagg 240
gcggcccgcg gggccggctc cgcagccgcg acagctcgtg cggccgcccc ggcaccccgg
300 gcgcggcgag cacggccaag ggcagcccga acggcgagtg cgggcgcggc
gagccgcagt 360 gcagccccgc ggggcccgag ggcccggcgc gggggcccaa
ggtgtcgttc tcgtgccgcg 420 gggcggcctc ggggcccgcg ccggggccgg
ggccggcgga ggaggcgggc agcgaggagg 480 cgggcccggc gggggagccg
cgcggcagcc aggccagctt catgcagcgc cagttcggcg 540 cgctcctgca
gccgggcgtc aacaagttct cgctgcggat gttcggcagc cagaaggccg 600
tggagcgcga gcaggagcgc gtcaagtcgg cgggggcctg gatcatccac ccgtacagcg
660 acttcaggtt ctactgggac ttcaccatgc tgctgttcat ggtgggaaac
ctcatcatca 720 tcccagtggg catcaccttc ttcaaggatg agaccactgc
cccgtggatc gtgttcaacg 780 tggtctcgga caccttcttc ctcatggacc
tggtgttgaa cttccgcacc ggcattgtga 840 tcgaggacaa cacggagatc
atcctggacc ccgagaagat caagaagaag tatctgcgca 900 cgtggttcgt
ggtggacttc gtgtcctcca tccccgtgga ctacatcttc cttatcgtgg 960
agaagggcat tgactccgag gtctacaaga cggcacgcgc cctgcgcatc gtgcgcttca
1020 ccaagatcct cagcctcctg cggctgctgc gcctctcacg cctgatccgc
tacatccatc 1080 agtgggagga gatcttccac atgacctatg acctggccag
cgcggtgatg aggatctgca 1140 atctcatcag catgatgctg ctgctctgcc
actgggacgg ctgcctgcag ttcctggtgc 1200 ctatgctgca ggacttcccg
cgcaactgct gggtgtccat caatggcatg gtgaaccact 1260 cgtggagtga
actgtactcc ttcgcactct tcaaggccat gagccacatg ctgtgcatcg 1320
ggtacggccg gcaggcgccc gagagcatga cggacatctg gctgaccatg ctcagcatga
1380 ttgtgggtgc cacctgctac gccatgttca tcggccacgc cactgccctc
atccagtcgc 1440 tggactcctc gcggcgccag taccaggaga agtacaagca
ggtggagcag tacatgtcct 1500 tccacaagct gccagctgac ttccgccaga
agatccacga ctactatgag caccgttacc 1560 agggcaagat gtttgacgag
gacagcatcc tgggcgagct caacgggccc ctgcgggagg 1620 agatcgtcaa
cttcaactgc cggaagctgg tggcctccat gccgctgttc gccaacgccg 1680
accccaactt cgtcacggcc atgctgacca agctcaagtt cgaggtcttc cagccgggtg
1740 actacatcat ccgcgaaggc accatcggga agaagatgta cttcatccag
cacggcgtgg 1800 tcagcgtgct cactaagggc aacaaggaga tgaagctgtc
cgatggctcc tacttcgggg 1860 agatctgcct gctcacccgg ggccgccgca
cggcgagcgt gcgggctgac acctactgcc 1920 gcctctattc gctgagcgtg
gacaacttca acgaggtgct ggaggagtac cccatgatgc 1980 ggcgcgcctt
cgagacggtg gccatcgacc gcctggaccg catcggcaag aagaattcca 2040
tcctcctgca caaggtgcag catgacctca actcgggcgt attcaacaac caggagaacg
2100 ccatcatcca ggagatcgtc aagtacgacc gcgagatggt gcagcaggcc
gagctgggtc 2160 agcgcgtggg cctcttcccg ccgccgccgc cgccgccgca
ggtcacctcg gccatcgcca 2220 cgctgcagca ggcggcggcc atgagcttct
gcccgcaggt ggcgcggccg ctcgtggggc 2280 cgctggcgct cggctcgccg
cgcctcgtgc gccgcccgcc cccggggccc gcacctgccg 2340 ccgcctcacc
cgggcccccg ccccccgcca gccccccggg cgcgcccgcc agcccccggg 2400
caccgcggac ctcgccctac ggcggcctgc ccgccgcccc ccttgctggg cccgccctgc
2460 ccgcgcgccg cctgagccgc gcgtcgcgcc cactgtccgc ctcgcagccc
tcgctgcctc 2520 acggcgcccc cggccccgcg gcctccacac gcccggccag
cagctccaca ccgcgcttgg 2580 ggcccacgcc cgctgcccgg gccgccgcgc
ccagcccgga ccgcagggac tcggcctcac 2640 ccggcgccgc cggcggcctg
gacccccagg actccgcgcg ctcgcgcctc tcgtccaact 2700 tgtgaccctc
gccgaccgcc ccgcgggccc aggcgggccg ggggcggggc cgtcatccag 2760
accaaagcca tgccattgcg ctgccccggc cgccagtccg cccagaagcc atagacgaga
2820 cgtaggtagc cgtagttgga cggacgggca gggccggcgg ggcagccccc
tccgcgcccc 2880 cggccgtccc ccctcatcgc cccgcgccca cccccatcgc
ccctgccccc ggcggcggcc 2940 tcgcgtgcga gggggctccc ttcacctcgg
tgcctcagtt cccccagctg taagacaggg 3000 acggggcggc ccagtggctg
agaggagccg gctgtggagc cccgcccgcc ccccaccctc 3060 taggtggccc
ccgtccgagg aggatcgttt tctaagtgca atacttggcc cgccggcttc 3120
ccgctgcccc catcgcgctc acgcaataac cggcccggcc cccgtccgcg cgcgtccccc
3180 ggtgacctcg gggagcagca ccccgcctcc ctccagcact ggcaccgaga
ggcaggcctg 3240 gctgcgcagg gcgcgggggg gaggctgggg tcccgccgcc
gtgatgaatg tactgacgag 3300 ccgaggcagc agtgccccca ccgtggcccc
ccacgcccca ttaaccccca cacccccatt 3360 ccgcgcaata aa 3372
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 3
<211> LENGTH: 1203 <212> TYPE: PRT <213>
ORGANISM: Homo sapiens <400> SEQUENCE: 3 Met Asp Lys Leu Pro
Pro Ser Met Arg Lys Arg Leu Tyr Ser Leu Pro 1 5 10 15 Gln Gln Val
Gly Ala Lys Ala Trp Ile Met Asp Glu Glu Glu Asp Ala 20 25 30 Glu
Glu Glu Gly Ala Gly Gly Arg Gln Asp Pro Ser Arg Arg Ser Ile 35 40
45 Arg Leu Arg Pro Leu Pro Ser Pro Ser Pro Ser Ala Ala Ala Gly Gly
50 55 60 Thr Glu Ser Arg Ser Ser Ala Leu Gly Ala Ala Asp Ser Glu
Gly Pro 65 70 75 80 Ala Arg Gly Ala Gly Lys Ser Ser Thr Asn Gly Asp
Cys Arg Arg Phe 85 90 95 Arg Gly Ser Leu Ala Ser Leu Gly Ser Arg
Gly Gly Gly Ser Gly Gly 100 105 110 Thr Gly Ser Gly Ser Ser His Gly
His Leu His Asp Ser Ala Glu Glu 115 120 125 Arg Arg Leu Ile Ala Glu
Gly Asp Ala Ser Pro Gly Glu Asp Arg Thr 130 135 140 Pro Pro Gly Leu
Ala Ala Glu Pro Glu Arg Pro Gly Ala Ser Ala Gln 145 150 155 160 Pro
Ala Ala Ser Pro Pro Pro Pro Gln Gln Pro Pro Gln Pro Ala Ser 165 170
175 Ala Ser Cys Glu Gln Pro Ser Val Asp Thr Ala Ile Lys Val Glu Gly
180 185 190 Gly Ala Ala Ala Gly Asp Gln Ile Leu Pro Glu Ala Glu Val
Arg Leu 195 200 205 Gly Gln Ala Gly Phe Met Gln Arg Gln Phe Gly Ala
Met Leu Gln Pro 210 215 220 Gly Val Asn Lys Phe Ser Leu Arg Met Phe
Gly Ser Gln Lys Ala Val 225 230 235 240 Glu Arg Glu Gln Glu Arg Val
Lys Ser Ala Gly Phe Trp Ile Ile His 245 250 255 Pro Tyr Ser Asp Phe
Arg Phe Tyr Trp Asp Leu Thr Met Leu Leu Leu 260 265 270 Met Val Gly
Asn Leu Ile Ile Ile Pro Val Gly Ile Thr Phe Phe Lys 275 280 285 Asp
Glu Asn Thr Thr Pro Trp Ile Val Phe Asn Val Val Ser Asp Thr 290 295
300 Phe Phe Leu Ile Asp Leu Val Leu Asn Phe Arg Thr Gly Ile Val Val
305 310 315 320 Glu Asp Asn Thr Glu Ile Ile Leu Asp Pro Gln Arg Ile
Lys Met Lys 325 330 335 Tyr Leu Lys Ser Trp Phe Met Val Asp Phe Ile
Ser Ser Ile Pro Val 340 345 350 Asp Tyr Ile Phe Leu Ile Val Glu Thr
Arg Ile Asp Ser Glu Val Tyr 355 360 365 Lys Thr Ala Arg Ala Leu Arg
Ile Val Arg Phe Thr Lys Ile Leu Ser 370 375 380 Leu Leu Arg Leu Leu
Arg Leu Ser Arg Leu Ile Arg Tyr Ile His Gln 385 390 395 400 Trp Glu
Glu Ile Phe His Met Thr Tyr Asp Leu Ala Ser Ala Val Val 405 410 415
Arg Ile Val Asn Leu Ile Gly Met Met Leu Leu Leu Cys His Trp Asp 420
425 430 Gly Cys Leu Gln Phe Leu Val Pro Met Leu Gln Asp Phe Pro Asp
Asp 435 440 445 Cys Trp Val Ser Ile Asn Asn Met Val Asn Asn Ser Trp
Gly Lys Gln 450 455 460 Tyr Ser Tyr Ala Leu Phe Lys Ala Met Ser His
Met Leu Cys Ile Gly 465 470 475 480 Tyr Gly Arg Gln Ala Pro Val Gly
Met Ser Asp Val Trp Leu Thr Met
485 490 495 Leu Ser Met Ile Val Gly Ala Thr Cys Tyr Ala Met Phe Ile
Gly His 500 505 510 Ala Thr Ala Leu Ile Gln Ser Leu Asp Ser Ser Arg
Arg Gln Tyr Gln 515 520 525 Glu Lys Tyr Lys Gln Val Glu Gln Tyr Met
Ser Phe His Lys Leu Pro 530 535 540 Pro Asp Thr Arg Gln Arg Ile His
Asp Tyr Tyr Glu His Arg Tyr Gln 545 550 555 560 Gly Lys Met Phe Asp
Glu Glu Ser Ile Leu Gly Glu Leu Ser Glu Pro 565 570 575 Leu Arg Glu
Glu Ile Ile Asn Phe Asn Cys Arg Lys Leu Val Ala Ser 580 585 590 Met
Pro Leu Phe Ala Asn Ala Asp Pro Asn Phe Val Thr Ser Met Leu 595 600
605 Thr Lys Leu Arg Phe Glu Val Phe Gln Pro Gly Asp Tyr Ile Ile Arg
610 615 620 Glu Gly Thr Ile Gly Lys Lys Met Tyr Phe Ile Gln His Gly
Val Val 625 630 635 640 Ser Val Leu Thr Lys Gly Asn Lys Glu Thr Lys
Leu Ala Asp Gly Ser 645 650 655 Tyr Phe Gly Glu Ile Cys Leu Leu Thr
Arg Gly Arg Arg Thr Ala Ser 660 665 670 Val Arg Ala Asp Thr Tyr Cys
Arg Leu Tyr Ser Leu Ser Val Asp Asn 675 680 685 Phe Asn Glu Val Leu
Glu Glu Tyr Pro Met Met Arg Arg Ala Phe Glu 690 695 700 Thr Val Ala
Leu Asp Arg Leu Asp Arg Ile Gly Lys Lys Asn Ser Ile 705 710 715 720
Leu Leu His Lys Val Gln His Asp Leu Asn Ser Gly Val Phe Asn Tyr 725
730 735 Gln Glu Asn Glu Ile Ile Gln Gln Ile Val Gln His Asp Arg Glu
Met 740 745 750 Ala His Cys Ala His Arg Val Gln Ala Ala Ala Ser Ala
Thr Pro Thr 755 760 765 Pro Thr Pro Val Ile Trp Thr Pro Leu Ile Gln
Ala Pro Leu Gln Ala 770 775 780 Ala Ala Ala Thr Thr Ser Val Ala Ile
Ala Leu Thr His His Pro Arg 785 790 795 800 Leu Pro Ala Ala Ile Phe
Arg Pro Pro Pro Gly Ser Gly Leu Gly Asn 805 810 815 Leu Gly Ala Gly
Gln Thr Pro Arg His Leu Lys Arg Leu Gln Ser Leu 820 825 830 Ile Pro
Ser Ala Leu Gly Ser Ala Ser Pro Ala Ser Ser Pro Ser Gln 835 840 845
Val Asp Thr Pro Ser Ser Ser Ser Phe His Ile Gln Gln Leu Ala Gly 850
855 860 Phe Ser Ala Pro Ala Gly Leu Ser Pro Leu Leu Pro Ser Ser Ser
Ser 865 870 875 880 Ser Pro Pro Pro Gly Ala Cys Gly Ser Pro Ser Ala
Pro Thr Pro Ser 885 890 895 Ala Gly Val Ala Ala Thr Thr Ile Ala Gly
Phe Gly His Phe His Lys 900 905 910 Ala Leu Gly Gly Ser Leu Ser Ser
Ser Asp Ser Pro Leu Leu Thr Pro 915 920 925 Leu Gln Pro Gly Ala Arg
Ser Pro Gln Ala Ala Gln Pro Ser Pro Ala 930 935 940 Pro Pro Gly Ala
Arg Gly Gly Leu Gly Leu Pro Glu His Phe Leu Pro 945 950 955 960 Pro
Pro Pro Ser Ser Arg Ser Pro Ser Ser Ser Pro Gly Gln Leu Gly 965 970
975 Gln Pro Pro Gly Glu Leu Ser Leu Gly Leu Ala Thr Gly Pro Leu Ser
980 985 990 Thr Pro Glu Thr Pro Pro Arg Gln Pro Glu Pro Pro Ser Leu
Val Ala 995 1000 1005 Gly Ala Ser Gly Gly Ala Ser Pro Val Gly Phe
Thr Pro Arg Gly Gly 1010 1015 1020 Leu Ser Pro Pro Gly His Ser Pro
Gly Pro Pro Arg Thr Phe Pro Ser 1025 1030 1035 1040 Ala Pro Pro Arg
Ala Ser Gly Ser His Gly Ser Leu Leu Leu Pro Pro 1045 1050 1055 Ala
Ser Ser Pro Pro Pro Pro Gln Val Pro Gln Arg Arg Gly Thr Pro 1060
1065 1070 Pro Leu Thr Pro Gly Arg Leu Thr Gln Asp Leu Lys Leu Ile
Ser Ala 1075 1080 1085 Ser Gln Pro Ala Leu Pro Gln Asp Gly Ala Gln
Thr Leu Arg Arg Ala 1090 1095 1100 Ser Pro His Ser Ser Gly Glu Ser
Met Ala Ala Phe Pro Leu Phe Pro 1105 1110 1115 1120 Arg Ala Gly Gly
Gly Ser Gly Gly Ser Gly Ser Ser Gly Gly Leu Gly 1125 1130 1135 Pro
Pro Gly Arg Pro Tyr Gly Ala Ile Pro Gly Gln His Val Thr Leu 1140
1145 1150 Pro Arg Lys Thr Ser Ser Gly Ser Leu Pro Pro Pro Leu Ser
Leu Phe 1155 1160 1165 Gly Ala Arg Ala Thr Ser Ser Gly Gly Pro Pro
Leu Thr Ala Gly Pro 1170 1175 1180 Gln Arg Glu Pro Gly Ala Arg Pro
Glu Pro Val Arg Ser Lys Leu Pro 1185 1190 1195 1200 Ser Asn Leu
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 4
<211> LENGTH: 5065 <212> TYPE: DNA <213>
ORGANISM: Homo sapiens <400> SEQUENCE: 4 ggtcgctggg
ctccgctcgg ttgcggcggg agccccggga cgggccggac gggccggggc 60
agaggaggcg aggcgagctc gcgggtggcc agccacaaag cccgggcggc gagacagacg
120 gacagccagc cctcccgcgg gacgcacgcc cgggacccgc gcgggccgtg
cgctctgcac 180 tccggagcgg ttccctgagc gccgcggccg cagagcctct
ccggccggcg cccattgttc 240 cccgcggggg cggggcgcct ggagccgggc
ggcgcgccgc gcccctgaac gccagaggga 300 gggagggagg caagaaggga
gcgcggggtc cccgcgccca gccgggcccg ggaggaggtg 360 tagcgcggcg
agcccgggga ctcggagcgg gactaggatc ctccccgcgg cgcgcagcct 420
gcccaagcat gggcgcctga ggctgccccc acgccggcgg caaaggacgc gtccccacgg
480 gcggactgac cggcgggcgg acctggagcc cgtccgcggc gccgcgctcc
tgcccccggc 540 ccggtccgac cccggcccct ggcgccatgg acaagctgcc
gccgtccatg cgcaagcggc 600 tctacagcct cccgcagcag gtgggggcca
aggcgtggat catggacgag gaagaggacg 660 ccgaggagga gggggccggg
ggccgccaag accccagccg caggagcatc cggctgcggc 720 cactgccctc
gccctccccc tcggcggccg cgggtggcac ggagtcccgg agctcggccc 780
tcggggcagc ggacagcgaa gggccggccc gcggcgcggg caagtccagc acgaacggcg
840 actgcaggcg cttccgcggg agcctggcct cgctgggcag ccggggcggc
ggcagcggcg 900 gcacggggag cggcagcagt cacggacacc tgcatgactc
cgcggaggag cggcggctca 960 tcgccgaggg cgacgcgtcc cccggcgagg
acaggacgcc cccaggcctg gcggccgagc 1020 ccgagcgccc cggcgcctcg
gcgcagcccg cagcctcgcc gccgccgccc cagcagccac 1080 cgcagccggc
ctccgcctcc tgcgagcagc cctcggtgga caccgctatc aaagtggagg 1140
gaggcgcggc tgccggcgac cagatcctcc cggaggccga ggtgcgcctg ggccaggccg
1200 gcttcatgca gcgccagttc ggggccatgc tccaacccgg ggtcaacaaa
ttctccctaa 1260 ggatgttcgg cagccagaaa gccgtggagc gcgaacagga
gagggtcaag tcggccggat 1320 tttggattat ccacccctac agtgacttca
gattttactg ggacctgacc atgctgctgc 1380 tgatggtggg aaacctgatt
atcattcctg tgggcatcac cttcttcaag gatgagaaca 1440 ccacaccctg
gattgtcttc aatgtggtgt cagacacatt cttcctcatc gacttggtcc 1500
tcaacttccg cacagggatc gtggtggagg acaacacaga gatcatcctg gacccgcagc
1560 ggattaaaat gaagtacctg aaaagctggt tcatggtaga tttcatttcc
tccatccccg 1620 tggactacat cttcctcatt gtggagacac gcatcgactc
ggaggtctac aagactgccc 1680 gggccctgcg cattgtccgc ttcacgaaga
tcctcagcct cttacgcctg ttacgcctct 1740 cccgcctcat tcgatatatt
caccagtggg aagagatctt ccacatgacc tacgacctgg 1800 ccagcgccgt
ggtgcgcatc gtgaacctca tcggcatgat gctcctgctc tgccactggg 1860
acggctgcct gcagttcctg gtacccatgc tacaggactt ccctgacgac tgctgggtgt
1920 ccatcaacaa catggtgaac aactcctggg ggaagcagta ctcctacgcg
ctcttcaagg 1980 ccatgagcca catgctgtgc atcggctacg ggcggcaggc
gcccgtgggc atgtccgacg 2040 tctggctcac catgctcagc atgatcgtgg
gtgccacctg ctacgccatg ttcattggcc 2100 acgccactgc cctcatccag
tccctggact cctcccggcg ccagtaccag gaaaagtaca 2160 agcaggtgga
gcagtacatg tcctttcaca agctcccgcc cgacacccgg cagcgcatcc 2220
acgactacta cgagcaccgc taccagggca agatgttcga cgaggagagc atcctgggcg
2280 agctaagcga gcccctgcgg gaggagatca tcaactttaa ctgtcggaag
ctggtggcct 2340 ccatgccact gtttgccaat gcggacccca acttcgtgac
gtccatgctg accaagctgc 2400 gtttcgaggt cttccagcct ggggactaca
tcatccggga aggcaccatt ggcaagaaga 2460 tgtacttcat ccagcatggc
gtggtcagcg tgctcaccaa gggcaacaag gagaccaagc 2520 tggccgacgg
ctcctacttt ggagagatct gcctgctgac ccggggccgg cgcacagcca 2580
gcgtgagggc cgacacctac tgccgcctct actcgctgag cgtggacaac ttcaatgagg
2640 tgctggagga gtaccccatg atgcgaaggg ccttcgagac cgtggcgctg
gaccgcctgg 2700 accgcattgg caagaagaac tccatcctcc tccacaaagt
ccagcacgac ctcaactccg 2760 gcgtcttcaa ctaccaggag aatgagatca
tccagcagat tgtgcagcat gaccgggaga 2820 tggcccactg cgcgcaccgc
gtccaggctg ctgcctctgc caccccaacc cccacgcccg 2880 tcatctggac
cccgctgatc caggcaccac tgcaggctgc cgctgccacc acttctgtgg 2940
ccatagccct cacccaccac cctcgcctgc ctgctgccat cttccgccct cccccaggat
3000 ctgggctggg caacctcggt gccgggcaga cgccaaggca cctgaaacgg
ctgcagtccc 3060 tgatcccttc tgcgctgggc tccgcctcgc ccgccagcag
cccgtcccag gtggacacac 3120 cgtcttcatc ctccttccac atccaacagc
tggctggatt ctctgccccc gctggactga 3180 gcccactcct gccctcatcc
agctcctccc caccccccgg ggcctgtggc tccccctcgg 3240 ctcccacacc
atcagctggc gtagccgcca ccaccatagc cgggtttggc cacttccaca 3300
aggcgctggg tggctccctg tcctcctccg actctcccct gctcaccccg ctgcagccag
3360 gcgcccgctc cccgcaggct gcccagccat ctcccgcgcc acccggggcc
cggggaggcc 3420 tgggactccc ggagcacttc ctgccacccc caccctcatc
cagatccccg tcatctagcc 3480 ccgggcagct gggccagcct cccggggagt
tgtccctagg tctggccact ggcccactga 3540 gcacgccaga gacaccccca
cggcagcctg agccgccgtc ccttgtggca ggggcctctg 3600 ggggggcttc
ccctgtaggc tttactcccc gaggaggtct cagcccccct ggccacagcc 3660
caggcccccc aagaaccttc ccgagtgccc cgccccgggc ctctggctcc cacggatcct
3720 tgctcctgcc acctgcatcc agccccccac caccccaggt cccccagcgc
cggggcacac 3780 ccccgctcac ccccggccgc ctcacccagg acctcaagct
catctccgcg tctcagccag 3840 ccctgcctca ggacggggcg cagactctcc
gcagagcctc cccgcactcc tcaggggagt 3900 ccatggctgc cttcccgctc
ttccccaggg ctgggggtgg cagcgggggc agtgggagca 3960 gcgggggcct
cggtccccct gggaggccct atggtgccat ccccggccag cacgtcactc 4020
tgcctcggaa gacatcctca ggttctttgc caccccctct gtctttgttt ggggcaagag
4080 ccacctcttc tggggggccc cctctgactg ctggacccca gagggaacct
ggggccaggc 4140 ctgagccagt gcgctccaaa ctgccatcca atctatgagc
tgggcccttc cttccctctt 4200 ctttcttctt ttctctccct tccttcttcc
ttcaggttta actgtgatta ggagatatac 4260 caataacagt aataattatt
taaaaaacca cacacaccag aaaaacaaaa gacagcagaa 4320 aataaccagg
tattcttaga gctatagatt tttggtcact tgcttttata gactatttta 4380
atactcagca ctagagggag ggagggggag ggaggaggga gcaggcaggt cccaaatgca
4440 aaagccagag aaaggcagat ggggtctccg gggctgggca ggggtgggag
tggccagtgt 4500 tggcggttct tagagcagat gtgtcattgt gttcatttag
agaaacagct gccatcagcc 4560 cgttagctgt aacttggagc tccactctgc
ccccagaaag gggctgccct ggggtgtgcc 4620 ctggggagcc tcagaagcct
gcgaccttgg gagaaaaggg ccagggccct gagggcctag 4680 cattttttct
actgtaaacg tagcaagatc tgtatatgaa tatgtatatg tatatgtatg 4740
taagatgtgt atatgtatag ctatgtagcg ctctgtagag ccatgtagat agccactcac
4800 atgtgcgcac acgtgtgcgg tctagtttaa tcccatgttg acaggatgcc
caggtcacct 4860 tacacccagc aacccgcctt ggcccgcagg ctgtgcactg
catggtctag ggacgttctc 4920 tctccagtcc tcagggaaga ggacgccagg
acttcgcagc aggccccctc tctccccatc 4980 tctggtctca aagccagtcc
cagcctgacc tctcaccaca cggaagtgga agactcccct 5040 ttcctagggc
ctcaagcaca caccg 5065 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 5 <211> LENGTH: 863 <212> TYPE:
PRT <213> ORGANISM: Murinae gen. sp. <400> SEQUENCE: 5
Met Asp Ala Arg Gly Gly Gly Gly Arg Pro Gly Asp Ser Pro Gly Thr 1 5
10 15 Thr Pro Ala Pro Gly Pro Pro Pro Pro Pro Pro Pro Pro Ala Pro
Pro 20 25 30 Gln Pro Gln Pro Pro Pro Ala Pro Pro Pro Asn Pro Thr
Thr Pro Ser 35 40 45 His Pro Glu Ser Ala Asp Glu Pro Gly Pro Arg
Ala Arg Leu Cys Ser 50 55 60 Arg Asp Ser Ala Cys Thr Pro Gly Ala
Ala Lys Gly Gly Ala Asn Gly 65 70 75 80 Glu Cys Gly Arg Gly Glu Pro
Gln Cys Ser Pro Glu Gly Pro Ala Arg 85 90 95 Gly Pro Lys Val Ser
Phe Ser Cys Arg Gly Ala Ala Ser Gly Pro Ser 100 105 110 Ala Ala Glu
Glu Ala Gly Ser Glu Glu Ala Gly Pro Ala Gly Glu Pro 115 120 125 Arg
Gly Ser Gln Ala Ser Phe Leu Gln Arg Gln Phe Gly Ala Leu Leu 130 135
140 Gln Pro Gly Val Asn Lys Phe Ser Leu Arg Met Phe Gly Ser Gln Lys
145 150 155 160 Ala Val Glu Arg Glu Gln Glu Arg Val Lys Ser Ala Gly
Ala Trp Ile 165 170 175 Ile His Pro Tyr Ser Asp Phe Arg Phe Tyr Trp
Asp Phe Thr Met Leu 180 185 190 Leu Phe Met Val Gly Asn Leu Ile Ile
Ile Pro Val Gly Ile Thr Phe 195 200 205 Phe Lys Asp Glu Thr Thr Ala
Pro Trp Ile Val Phe Asn Val Val Ser 210 215 220 Asp Thr Phe Phe Leu
Met Asp Leu Val Leu Asn Phe Arg Thr Gly Ile 225 230 235 240 Val Ile
Glu Asp Asn Thr Glu Ile Ile Leu Asp Pro Glu Lys Ile Lys 245 250 255
Lys Lys Tyr Leu Arg Thr Trp Phe Val Val Asp Phe Val Ser Ser Ile 260
265 270 Pro Val Asp Tyr Ile Phe Leu Ile Val Glu Lys Gly Ile Asp Ser
Glu 275 280 285 Val Tyr Lys Thr Ala Arg Ala Leu Arg Ile Val Arg Phe
Thr Lys Ile 290 295 300 Leu Ser Leu Leu Arg Leu Leu Arg Leu Ser Arg
Leu Ile Arg Tyr Ile 305 310 315 320 His Gln Trp Glu Glu Ile Phe His
Met Thr Tyr Asp Leu Ala Ser Ala 325 330 335 Val Met Arg Ile Cys Asn
Leu Ile Ser Met Met Leu Leu Leu Cys His 340 345 350 Trp Asp Gly Cys
Leu Gln Phe Leu Val Pro Met Leu Gln Asp Phe Pro 355 360 365 Ser Asp
Cys Trp Val Ser Ile Asn Asn Met Val Asn His Ser Trp Ser 370 375 380
Glu Leu Tyr Ser Phe Ala Leu Phe Lys Ala Met Ser His Met Leu Cys 385
390 395 400 Ile Gly Tyr Gly Arg Gln Ala Pro Glu Ser Met Thr Asp Ile
Trp Leu 405 410 415 Thr Met Leu Ser Met Ile Val Gly Ala Thr Cys Tyr
Ala Met Phe Ile 420 425 430 Gly His Ala Thr Ala Leu Ile Gln Ser Leu
Asp Ser Ser Arg Arg Gln 435 440 445 Tyr Gln Glu Lys Tyr Lys Gln Val
Glu Gln Tyr Met Ser Phe His Lys 450 455 460 Leu Pro Ala Asp Phe Arg
Gln Lys Ile His Asp Tyr Tyr Glu His Arg 465 470 475 480 Tyr Gln Gly
Lys Met Phe Asp Glu Asp Ser Ile Leu Gly Glu Leu Asn 485 490 495 Gly
Pro Leu Arg Glu Glu Ile Val Asn Phe Asn Cys Arg Lys Leu Val 500 505
510
Ala Ser Met Pro Leu Phe Ala Asn Ala Asp Pro Asn Phe Val Thr Ala 515
520 525 Met Leu Thr Lys Leu Lys Phe Glu Val Phe Gln Pro Gly Asp Tyr
Ile 530 535 540 Ile Arg Glu Gly Thr Ile Gly Lys Lys Met Tyr Phe Ile
Gln His Gly 545 550 555 560 Val Val Ser Val Leu Thr Lys Gly Asn Lys
Glu Met Lys Leu Ser Asp 565 570 575 Gly Ser Tyr Phe Gly Glu Ile Cys
Leu Leu Thr Arg Gly Arg Arg Thr 580 585 590 Ala Ser Val Arg Ala Asp
Thr Tyr Cys Arg Leu Tyr Ser Leu Ser Val 595 600 605 Asp Asn Phe Asn
Glu Val Leu Glu Glu Tyr Pro Met Met Arg Arg Ala 610 615 620 Phe Glu
Thr Val Ala Ile Asp Arg Leu Asp Arg Ile Gly Lys Lys Asn 625 630 635
640 Ser Ile Leu Leu His Lys Val Gln His Asp Leu Ser Ser Gly Val Phe
645 650 655 Asn Asn Gln Glu Asn Ala Ile Ile Gln Glu Ile Val Lys Tyr
Asp Arg 660 665 670 Glu Met Val Gln Gln Ala Glu Leu Gly Gln Arg Val
Gly Leu Phe Pro 675 680 685 Pro Pro Pro Pro Pro Gln Val Thr Ser Ala
Ile Ala Thr Leu Gln Gln 690 695 700 Ala Val Ala Met Ser Phe Cys Pro
Gln Val Ala Arg Pro Leu Val Gly 705 710 715 720 Pro Leu Ala Leu Gly
Ser Pro Arg Leu Val Arg Arg Ala Pro Pro Gly 725 730 735 Pro Leu Pro
Pro Ala Ala Ser Pro Gly Pro Pro Ala Ala Ser Pro Pro 740 745 750 Ala
Ala Pro Ser Ser Pro Arg Ala Pro Arg Thr Ser Pro Tyr Gly Val 755 760
765 Pro Gly Ser Pro Ala Thr Arg Val Gly Pro Ala Leu Pro Ala Arg Arg
770 775 780 Leu Ser Arg Ala Ser Arg Pro Leu Ser Ala Ser Gln Pro Ser
Leu Pro 785 790 795 800 His Gly Val Pro Ala Pro Ser Pro Ala Ala Ser
Ala Arg Pro Ala Ser 805 810 815 Ser Ser Thr Pro Arg Leu Gly Pro Ala
Pro Thr Ala Arg Thr Ala Ala 820 825 830 Pro Ser Pro Asp Arg Arg Asp
Ser Ala Ser Pro Gly Ala Ala Ser Gly 835 840 845 Leu Asp Pro Leu Asp
Ser Ala Arg Ser Arg Leu Ser Ser Asn Leu 850 855 860 <200>
SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 6 <211>
LENGTH: 3102 <212> TYPE: DNA <213> ORGANISM: Murinae
gen. sp. <400> SEQUENCE: 6 ccgctccgct ccgcactgcc cggcgccgcc
tcgccatgga tgcgcgcggg ggcggcgggc 60 ggccgggcga tagtccgggc
acgacccctg cgccggggcc gccgccaccg ccgccgccgc 120 ccgcgccccc
tcagcctcag ccaccacccg cgccaccccc gaaccccacg accccctcgc 180
acccggagtc ggcggacgag cccggcccgc gcgcccggct ctgcagccgc gacagcgcct
240 gcacccctgg cgcggccaag ggcggcgcga atggcgagtg cgggcgcggg
gagccgcagt 300 gcagccccga gggccccgcg cgcggcccca aggtttcgtt
ctcatgccgc ggggcggcct 360 ccgggccctc ggcggccgag gaggcgggca
gcgaggaggc gggcccggcg ggtgagccgc 420 gcggcagcca ggctagcttc
ctgcagcgcc aattcggggc gcttctgcag cccggcgtca 480 acaagttctc
cctgcggatg ttcggcagcc agaaggccgt ggagcgcgag caggaacgcg 540
tgaagtcggc gggggcctgg atcatccacc cctacagcga cttcaggttc tactgggact
600 tcaccatgct gttgttcatg gtgggaaatc tcattatcat tcccgtgggc
atcactttct 660 tcaaggacga gaccaccgcg ccctggatcg tcttcaacgt
ggtctcggac actttcttcc 720 tcatggactt ggtgttgaac ttccgcaccg
gcattgttat tgaggacaac acggagatca 780 tcctggaccc cgagaagata
aagaagaagt acttgcgtac gtggttcgtg gtggacttcg 840 tgtcatccat
cccggtggac tacatcttcc tcatagtgga gaagggaatc gactccgagg 900
tctacaagac agcgcgtgct ctgcgcatcg tgcgcttcac caagatcctc agtctgctgc
960 ggctgctgcg gctatcacgg ctcatccgat atatccacca gtgggaagag
attttccaca 1020 tgacctacga cctggcaagt gcagtgatgc gcatctgtaa
cctgatcagc atgatgctac 1080 tgctctgcca ctgggacggt tgcctgcagt
tcctggtgcc catgctgcaa gacttcccca 1140 gcgactgctg ggtgtccatc
aacaacatgg tgaaccactc gtggagcgag ctctactcgt 1200 tcgcgctctt
caaggccatg agccacatgc tgtgcatcgg ctacgggcgg caggcgcccg 1260
agagcatgac agacatctgg ctgaccatgc tcagcatgat cgtaggcgcc acctgctatg
1320 ccatgttcat tgggcacgcc actgcgctca tccagtccct ggattcgtca
cggcgccaat 1380 accaggagaa gtacaagcaa gtagagcaat acatgtcctt
ccacaaactg cccgctgact 1440 tccgccagaa gatccacgat tactatgaac
accggtacca agggaagatg tttgatgagg 1500 acagcatcct tggggaactc
aacgggccac tgcgtgagga gattgtgaac ttcaactgcc 1560 ggaagctggt
ggcttccatg ccgctgtttg ccaatgcaga ccccaacttc gtcacagcca 1620
tgctgacaaa gctcaaattt gaggtcttcc agcctggaga ttacatcatc cgagagggga
1680 ccatcgggaa gaagatgtac ttcatccagc atggggtggt gagcgtgctc
accaagggca 1740 acaaggagat gaagctgtcg gatggctcct atttcgggga
gatctgcttg ctcacgaggg 1800 gccggcgtac ggccagcgtg cgagctgaca
cctactgtcg cctctactca ctgagtgtgg 1860 acaatttcaa cgaggtgctg
gaggaatacc ccatgatgcg gcgtgccttt gagactgtgg 1920 ctattgaccg
gctagatcgc ataggcaaga agaactccat cttgctgcac aaggttcagc 1980
atgatctcag ctcaggtgtg ttcaacaacc aggagaatgc catcatccag gagattgtca
2040 aatatgaccg tgagatggtg cagcaggcag agcttggcca gcgtgtgggg
ctcttcccac 2100 caccgccacc accgcaggtc acatcggcca ttgccaccct
acagcaggct gtggccatga 2160 gcttctgccc gcaggtggcc cgcccgctcg
tggggcccct ggcgctaggc tccccacgcc 2220 tagtgcgccg cgcgccccca
gggcctctgc ctcctgcagc ctcgccaggg ccacccgcag 2280 caagcccccc
ggctgcaccc tcgagccctc gggcaccgcg gacctcaccc tacggtgtgc 2340
ctggctctcc ggcaacgcgc gtggggcccg cattgcccgc acgtcgcctg agccgcgcct
2400 cgcgcccact gtccgcctcg cagccctcgc tgccccatgg cgtgcccgcg
cccagccccg 2460 cggcctctgc gcgcccggcc agcagctcca cgccgcgcct
gggacccgca cccaccgccc 2520 ggaccgccgc gcccagtccg gaccgcaggg
actcagcctc gccgggcgct gccagtggcc 2580 tcgacccact ggactctgcg
cgctcgcgcc tctcttccaa cttgtgaccc ttgagcgccg 2640 ccccgcgggc
cgggcggggc cgtcatccac accaaagcca tgcctcgcgc cgcccgcccg 2700
tgcccgtgca gaagccatag agggacgtag gtagcttagg aggcgggcgg ccctgcgccc
2760 ggctgtcccc ccatcgccct gcgcccaccc ccatcgcccc tgccccagcg
gcggccgcac 2820 gggagaggga ggggtgcgat cacctcggtg cctcagcccc
aacctgggac agggacaggg 2880 cggccctggc cgaggacctg gctgtgcccc
gcatgtgcgg tggcctccga ggaagaatat 2940 ggatcaagtg caatacacgg
ccaagccggc gtgggggtga ggctgggtcc ccggccgtcg 3000 ccatgaatgt
actgacgagc cgaggcagca gtggccccca cgccccatta acccacaacc 3060
ccattccgcg caataaacga cagcattggc aaaaaaaaaa aa 3102 <200>
SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 7 <211>
LENGTH: 17 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <221> NAME/KEY: misc_feature
<222> LOCATION: (1)..(17) <223> OTHER INFORMATION:
Description of Artificial SequencePrimer <400> SEQUENCE: 7
gccaatacca ggagaag 17 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 8 <211> LENGTH: 19 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<221> NAME/KEY: misc_feature <222> LOCATION: (1)..(19)
<223> OTHER INFORMATION: Description of Artificial
SequencePrimer <400> SEQUENCE: 8 tgagtagagg cgacagtag 19
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 9
<211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <221> NAME/KEY:
misc_feature <222> LOCATION: (1)..(24) <223> OTHER
INFORMATION: Description of Artificial SequencePrimer <400>
SEQUENCE: 9 agtggcctcg acccactgga ctct 24 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 10 <211> LENGTH: 25
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <221> NAME/KEY: misc_feature <222>
LOCATION: (1)..(25) <223> OTHER INFORMATION: Description of
Artificial SequencePrimer <400> SEQUENCE: 10 ccgcctccta
agctacctac gtccc 25
* * * * *